

# **Advancements and Innovations in Cancer Management: A Comprehensive Perspective**

## **Authors:**

**Mehrdad Farrokhi**

ERIS Research Institute

**Fatemeh Taheri**

Islamic Azad University Pharmaceutical Sciences  
Branch

**Masoud Farrokhi**

ERIS Research Institute

**Zohreh Heydari**

Babol University of Medical Sciences

**Roya Darbani**

Malmö University

**Mandana Salbi**

Azad University of Falavarjan

**Sara Moghimi**

Bangalore University

**Behzad Garousi**

Tehran University of Medical Sciences

**Pooya Faranoush**

Islamic Azad University; Science & Research  
Branch

**Mohammad Faranoush**

Pediatric Growth and Development Research Center, Institute of Endocrinology, Iran University of Medical Sciences, Tehran, Iran

**Yasamin Khosravaninezhad**

Shiraz University of Medical Sciences

**Sarina Azimian Zavareh**

Shahid Beheshti University of Medical Sciences and Health Services

**Fatemeh Pournali Saadabad**

Khayyam University of Mashhad

**Negar Babapour**

Zanjan University of Medical Sciences

**Zahra Ghasemi**

Shahrekord University of Medical Sciences

**Amirhossein Esfahani**

Mazandaran University of Medical Sciences

**Samaneh Fouladi**

Children and Adolescents Health Research Center, Zahedan University of Medical Sciences

**Rasool Hamidi Choolabi**

Ahrar Institute of Technology and Higher Education

**Niki Mirfakhraei**

Urmia University of Medical Sciences

**Sima Noorali**

Shahid Beheshti University of Medical Sciences

**Kosar Bagtashi Baktash**

Tabriz University of Medical Sciences

**Mahrokh Janmohamadi**

Iran University of Medical Sciences

**Shiva Karimian**

Sanandaj Azad University

**Alireza Mohammad Bigloo**

Medical University of Kerman

**Nazila Ghorban Hosseini**

Tehran Medical Sciences Branch of Islamic Azad University

**Mahboobeh Majidnia**

Azad University Tehran Central Branch

**Haniyeh Ghasrsaz**

Mazandaran University of Medical Sciences

**Yasamin Moradi**

Keele University

**Ali Shahini**

Victor Philip Dahdaleh Institute of Genomic Medicine at McGill University

**Behnaz Dalvandi**

Islamic azad university, Medical Branch

**Zeynab Abdollahi**

Ahvaz Jundishapur University of Medical Sciences

**Haniyeh Taheri**

Islamic Azad University Pharmaceutical Sciences Branch

DR.MEHRDADFARROKHI

**Donya Pourkand**

Kermanshah University of Medical Sciences

**Elham Khakshour**

Sabzevar University of Medical Sciences

**Lida Zare Lahijan**

University of Tabriz

**Habib Azimi**

Tabriz University of Medical Sciences

**Mohammad Shahir Eftekhar**

Medical University of Qom

**S Sara Ketabi**

Birmingham City University

**Elham Davoudi**

University of Massachusetts Lowell

**Zahra Mohammadi**

Shahid Beheshti University of Medical Sciences

**Ali Bahari Golamkaboudi**

Guilan University of Medical Sciences

**Mohammad-Soroush Khorsand**

Azad University Science And Research Branch

**Babak Goodarzy**

Iran University of Medicine and Sciences

**Mohammad Amin Hashemnejad**

Alborz University of Medical Sciences

**Nikoo Emtiazi**

Iran University of Medical Sciences

ADVANCEMENTS AND INNOVATIONS IN CANCER MANAG...

**Seyed Mohammad Shahab Mirabedini**

Tehran Azad University

**Ehsan Mirsharifi**

Islamic Azad University Medical Branch of Tehran

**Hournaz Hassanzadeh**

Islamic Azad University, Tehran Medical Sciences

**Pedram Emami Shahrezaei**

Islamic Azad University Najafabad

**Mohammad Hosseini Hooshiar**

School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran

**Alireza Daneshvar**

Islamic Azad University Dental Branch of Tehran

**Abtin Akhtari**

Shahid Beheshti University of Medical Sciences

## **Book Details:**

**Publisher: Kindle**

**Publication Date: May 2024**

**Language: English**

**Dimensions: 5 x 0.39 x 8 inches**

**© Kindle and PreferPub 2024**

**ISBN-13: 979-8324709709**

**This peer-reviewed book is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specially the rights of translation, reprinting, result of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.**

## Contents

### Chapters

- 1- Advancements in the Management of Endocrine and Gastrointestinal Cancers
- 2- Advancements in the Management of Pediatric Cancers
- 3- Advancements in the Management of Skin Cancers
- 4- Advancements in the Management of Breast and Lung Cancers
- 5- Advancements in the Management of Oral Cancers
- 6- Advancements in the Management of Head and Neck Cancers
- 7- Advancements in the Management of Gynecologic Cancers
- 8- Advancements in Psycho-Oncology
- 9- Advancements in the Management of Other Cancers

## **1- ADVANCEMENTS IN THE MANAGEMENT OF ENDOCRINE AND GASTROINTESTINAL CANCERS**

### ***Background***

Endocrine and gastrointestinal cancers encompass a broad spectrum of malignancies affecting various organs and systems within the body. These cancers pose significant challenges due to their diverse presentations, complex treatment regimens, and variable prognoses. However, recent advancements in diagnostic techniques, therapeutic modalities, and molecular targeted therapies have revolutionized the management of these cancers, leading to improved outcomes and quality of life for patients. This comprehensive review explores the latest developments in the diagnosis, treatment, and ongoing research efforts in the field of endocrine and gastrointestinal cancers.

### ***Endocrine Cancers***

#### ***Thyroid Cancer***

Thyroid cancer is one of the most common endocrine malignancies, comprising different histological subtypes with varying prognoses.

Recent advancements in imaging modalities, such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), have enhanced the early detection and staging of thyroid cancer. Fine-needle aspiration biopsy (FNAB) remains the gold standard for diagnosing thyroid nodules, with molecular testing aiding in risk stratification and guiding treatment decisions.

Surgical management, including total thyroidectomy or lobectomy with lymph node dissection, remains the primary treatment for thyroid cancer. However, minimally invasive techniques, such as endoscopic thyroidectomy and robotic-assisted surgery, have gained popularity due to their lower morbidity and improved cosmetic outcomes. Radioactive iodine therapy (RAI) and external beam radiation therapy (EBRT) are utilized for adjuvant treatment in high-risk cases or for recurrent disease.

In recent years, molecular targeted therapies, such as tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR) and BRAF inhibitors, have revolutionized the management of advanced or metastatic thyroid cancer, particularly in cases refractory to conventional treatments. These targeted agents have shown promising results in improving progression-free survival and overall survival rates, with manageable toxicity profiles.

### **Adrenal Cancer**

Adrenal cancer, although rare, presents significant diagnostic and therapeutic challenges due to its aggressive nature and often late-stage presentation. Advanced imaging techniques, including CT, MRI, and PET, play a crucial role in accurately staging adrenal tumors and assessing the extent of disease spread.

Surgical resection remains the cornerstone of treatment for localized adrenal cancer, with adrenalectomy being the standard procedure. Laparoscopic and robotic-assisted techniques have emerged as safe and effective alternatives to open surgery, offering reduced operative times, shorter hospital stays, and faster recovery.

For patients with unresectable or metastatic disease, systemic therapy options, including chemotherapy, targeted therapy, and immunotherapy, are being investigated in clinical trials. In particular, immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have shown promising results in improving overall survival and durable responses in select patients.

### **Pancreatic Neuroendocrine Tumors (PNETs)**

Pancreatic neuroendocrine tumors (PNETs) are a heterogeneous group of tumors arising from

neuroendocrine cells in the pancreas. These tumors can be functional, secreting hormones such as insulin, glucagon, or gastrin, or non-functional, causing symptoms due to mass effect or metastasis.

Advancements in imaging modalities, including multiphase contrast-enhanced CT, MRI, and somatostatin receptor imaging (SRI) with  $^{68}\text{Ga}$ -DOTATATE PET/CT, have improved the detection and localization of PNETs. Endoscopic ultrasound (EUS) with fine-needle aspiration biopsy (FNAB) enables tissue sampling for histological diagnosis and molecular analysis.

Surgical resection remains the mainstay of treatment for localized PNETs, with options ranging from enucleation for small, well-differentiated tumors to pancreaticoduodenectomy or distal pancreatectomy for larger or multifocal lesions. Minimally invasive approaches, such as laparoscopic and robotic-assisted surgery, offer reduced morbidity and shorter hospital stays.

For metastatic or unresectable PNETs, systemic therapies, including somatostatin analogs, targeted therapies (e.g., everolimus, sunitinib), and peptide receptor radionuclide therapy (PRRT) with  $^{177}\text{Lu}$ -DOTATATE, have demonstrated efficacy in controlling tumor growth and prolonging progression-free survival. Additionally, peptide receptor radionuclide therapy (PRRT) with  $^{177}\text{Lu}$ -DOTATATE has

emerged as a promising treatment option for patients with advanced or progressive disease, offering targeted delivery of radiation to tumor cells expressing somatostatin receptors.

### **Parathyroid Cancer**

Parathyroid cancer is an extremely rare malignancy, accounting for less than 1% of all cases of primary hyperparathyroidism. The diagnosis of parathyroid cancer is challenging due to its indolent clinical course and histological resemblance to benign parathyroid adenomas.

Surgical resection with en bloc excision of the tumor and adjacent structures, including the ipsilateral thyroid lobe and central compartment lymph nodes, is the mainstay of treatment for parathyroid cancer. However, due to the high recurrence rates and risk of metastasis, adjuvant therapies, such as external beam radiation therapy (EBRT) and systemic therapy with cytotoxic chemotherapy or targeted agents, may be considered in select cases.

Recent molecular studies have identified potential therapeutic targets in parathyroid cancer, including mutations in the CDC73 (HRPT2) gene encoding parafibromin. Targeted therapies, such as cyclin-dependent kinase (CDK) inhibitors and mammalian target of rapamycin (mTOR) inhibitors, are being investigated in preclinical studies and early-phase clinical trials for their efficacy in inhibiting tumor growth and



metastasis.

### ***Gastrointestinal Cancers***

#### ***Colorectal Cancer (CRC)***

Colorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality worldwide. Advances in screening techniques, including colonoscopy, fecal immunochemical testing (FIT), and stool DNA testing, have enabled early detection of precancerous lesions and localized tumors, leading to improved survival rates.

Surgical resection with curative intent remains the primary treatment modality for early-stage CRC. However, the management of locally advanced or metastatic disease has evolved significantly with the introduction of neoadjuvant chemotherapy, targeted therapies, and immunotherapy.

Neoadjuvant chemoradiotherapy followed by total mesorectal excision (TME) has become the standard of care for patients with locally advanced rectal cancer, leading to improved rates of sphincter preservation and reduced local recurrence rates. In metastatic CRC, combination chemotherapy regimens, including fluoropyrimidine-based regimens with oxaliplatin or irinotecan, have been augmented with targeted agents such as anti-vascular endothelial growth factor (VEGF) monoclonal antibodies (e.g.,

bevacizumab) and anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (e.g., cetuximab, panitumumab).

Immunotherapy with immune checkpoint inhibitors, such as pembrolizumab and nivolumab, has demonstrated efficacy in a subset of patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) CRC, leading to durable responses and improved overall survival rates. Biomarker testing for MSI-H/dMMR status has become routine practice to identify eligible patients for immunotherapy.

#### ***Gastric Cancer***

Gastric cancer remains a significant global health burden, particularly in Eastern Asia and parts of Central and South America. Advances in endoscopic imaging, including narrow-band imaging (NBI) and magnifying endoscopy, have improved the detection and characterization of early gastric neoplasms, enabling endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) as curative treatment options for select patients.

Surgical resection with lymphadenectomy remains the cornerstone of treatment for localized gastric cancer. However, multimodal approaches incorporating perioperative chemotherapy or chemoradiotherapy have shown improved survival outcomes, particularly in patients with locally advanced or node-positive disease.

Targeted therapies, such as trastuzumab targeting human epidermal growth factor receptor 2 (HER2) and ramucirumab targeting vascular endothelial growth factor receptor 2 (VEGFR2), have demonstrated efficacy in selected patients with HER2-positive or VEGFR2-positive gastric cancer, respectively. Immunotherapy with immune checkpoint inhibitors, such as pembrolizumab and nivolumab, has shown promising results in advanced gastric cancer, particularly in patients with programmed death-ligand 1 (PD-L1)-positive tumors.

### ***Hepatocellular Carcinoma (HCC)***

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and a leading cause of cancer-related mortality worldwide. Advances in screening programs, including ultrasound surveillance and serum alpha-fetoprotein (AFP) testing, have enabled the early detection of HCC in high-risk populations, leading to improved outcomes with curative treatments such as surgical resection, liver transplantation, and local ablative therapies.

For patients with unresectable or advanced HCC, systemic therapies, including multikinase inhibitors (e.g., sorafenib, lenvatinib) and immune checkpoint inhibitors (e.g., nivolumab, pembrolizumab), have shown efficacy in improving overall survival and disease control. Combination regimens incorporating

targeted agents with immunotherapy or locoregional therapies, such as transarterial chemoembolization (TACE) or radioembolization, are being investigated in ongoing clinical trials. The advent of liquid biopsy techniques, including circulating tumor DNA (ctDNA) analysis and tumor-derived exosome profiling, holds promise for noninvasive monitoring of treatment response and disease progression in patients with HCC. Molecular profiling of HCC tumors has identified potential therapeutic targets, including mutations in the TERT promoter, CTNNB1 gene, and TP53 gene, which may guide the selection of personalized treatment strategies.

### ***Advancements in the Management of Pancreatic cancer***

#### ***Background***

Pancreatic cancer, also known as adenocarcinoma, arises as a malignant tumor developing in the epithelial cells of glandular structures within the pancreatic ductal cells. The majority of pancreatic cancers (PDAC), originating in the cells lining the ducts responsible for transporting digestive enzymes out of the pancreas, manifest as pancreatic ductal adenocarcinomas (PDAC), posing a fatal disease with a remote possibility of long-term survival.

Treatment options for PDAC include radiation

therapy, chemotherapy, and surgery. However, only 15% to 20% of patients qualify for surgery at the time of diagnosis. Unfortunately, due to the distinct molecular and cellular nature of pancreatic tumors, most are resistant to conventional treatments, with surgical patients often experiencing comorbidities and recurrence. Adjuvant chemotherapy, either in combination with radiation therapy or alone, has been widely employed in an attempt to improve outcomes.

### ***New Technologies Generating Novel Insights***

A recently developed technique known as mass cytometry by time-of-flight (CyTOF) begins with the incubation of fixed cell suspensions with antibodies tagged with heavy metals absent from typical biological systems. Scott Tanner and colleagues at the University of Toronto pioneered CyTOF. By quantifying stable isotope tags linked to target biomarkers, numerous proteins and gene transcripts can be simultaneously identified in individual cells, as a wide array of stable isotopes are available for use in metal-tagged antibodies. Through the use of heavy metal-conjugated antibodies and flow cytometry linked to a mass spectrometer, CyTOF enables the simultaneous detection of over 40 parameters in each cell for millions of cells. Using a time-of-flight mass spectrometer to identify each heavy metal based on the time it takes to reach a

sensor, cells are nebulized into liquid droplets, vaporized, ionized, and then passed through the system. By expanding the number of antigens that can be concurrently run for single-cell analysis, CyTOF can profile the composition and quantity of immune cells, allowing for high-dimensional profiling to precisely define cell types within the tumor microenvironment (TME).

Attributing the identification of CD105 as a critical marker for tumor-promoting/tumor-suppressive fibroblast behavior to the use of mass cytometry, millions of cells isolated from 19 murine PDAC tumors were compared against a library of over 40 recognized fibroblast and mesenchymal cell markers. It has been demonstrated that alterations in peripheral immune cell subsets may aid in tumor diagnosis and provide a readily applicable detection model for hepatocellular carcinoma (HCC) and PDAC.

### ***CyTOF Data Analysis***

Utilizing the FlowJo program, dead cells, debris, and doublets were excluded from manual gating data, resulting in the presence of only live single immune cells. The X-shift clustering algorithm was employed to categorize all cells into distinct phenotypes based on marker expression levels. Subsequently, cell types within each cluster were annotated on a heatmap of clusters and markers according to their marker expression.

### ***Conclusion***

Advancements in the management of endocrine and gastrointestinal cancers have transformed the landscape of cancer care, offering new diagnostic tools, treatment modalities, and therapeutic targets. From precision medicine approaches targeting specific genetic alterations to immunotherapy harnessing the power of the immune system, these innovations hold promise for improving outcomes and quality of life for patients with these challenging malignancies. Ongoing research efforts and collaborative initiatives are essential to further elucidate the underlying mechanisms of cancer pathogenesis and identify novel therapeutic strategies to combat these diseases effectively.

## **2- ADVANCEMENTS IN THE MANAGEMENT OF PEDIATRIC CANCERS**

### ***Background***

Pediatric cancers represent a diverse group of malignancies that affect children and adolescents, posing unique challenges due to their distinct biology, presentation, and treatment response compared to adult cancers. Over the past few decades, significant progress has been made in understanding the underlying mechanisms of pediatric cancers, leading to the development of novel diagnostic techniques, treatment modalities, and supportive care strategies. This comprehensive review explores the recent advancements in the management of pediatric cancers, focusing on improvements in diagnosis, treatment approaches, supportive care measures, and ongoing research efforts aimed at further enhancing outcomes for pediatric cancer patients.

### ***Advances in Diagnosis***

#### ***Molecular Profiling***

Recent advancements in molecular profiling techniques have revolutionized the diagnosis and classification of pediatric cancers, enabling

more accurate risk stratification and personalized treatment approaches. Next-generation sequencing (NGS) technologies allow for comprehensive analysis of the genomic landscape of pediatric tumors, identifying recurrent somatic mutations, chromosomal rearrangements, and actionable genetic alterations that can guide treatment decisions.

#### ***Liquid Biopsy***

Liquid biopsy techniques, such as circulating tumor DNA (ctDNA) analysis and tumor-derived exosome profiling, offer noninvasive methods for monitoring disease progression, detecting minimal residual disease, and identifying therapeutic targets in pediatric cancer patients. These minimally invasive approaches hold promise for real-time monitoring of treatment response and early detection of disease recurrence.

#### ***Imaging Modalities***

Advancements in imaging modalities, including magnetic resonance imaging (MRI), positron emission tomography (PET), and molecular imaging techniques, have improved the accuracy of tumor localization, staging, and response assessment in pediatric cancers. Functional imaging modalities, such as diffusion-weighted imaging (DWI) and dynamic contrast-enhanced MRI (DCE-MRI), provide valuable information about tumor microstructure, vascularity, and

metabolism, aiding in treatment planning and monitoring.

### **Treatment Modalities**

#### **Surgery**

Surgical resection remains a cornerstone of treatment for many pediatric solid tumors, including neuroblastoma, Wilms tumor, and osteosarcoma. Advances in surgical techniques, including minimally invasive approaches and intraoperative imaging technologies, have improved surgical outcomes and reduced morbidity in pediatric cancer patients.

#### **Chemotherapy**

Chemotherapy continues to play a central role in the treatment of pediatric cancers, both as adjuvant therapy following surgery and as primary treatment for metastatic or unresectable disease. The development of novel chemotherapeutic agents, targeted drug delivery systems, and combination chemotherapy regimens has led to improved survival rates and reduced treatment-related toxicity in pediatric cancer patients.

#### **Radiation Therapy**

Radiation therapy is an essential component of multimodal treatment approaches for many pediatric cancers, including brain tumors,

sarcomas, and lymphomas. Technological advancements, such as intensity-modulated radiation therapy (IMRT), proton therapy, and stereotactic radiosurgery (SRS), allow for precise delivery of radiation to tumor targets while sparing adjacent normal tissues, thereby minimizing treatment-related toxicities.

#### **Immunotherapy**

Immunotherapy has emerged as a promising treatment modality for pediatric cancers, harnessing the power of the immune system to recognize and eliminate tumor cells. Chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint inhibitors, and tumor-targeted antibodies have shown encouraging results in clinical trials for pediatric leukemias, lymphomas, and solid tumors, leading to durable responses and improved survival rates in select patients.

#### **Supportive Care Measures**

##### **Palliative Care**

Palliative care plays a critical role in the comprehensive management of pediatric cancer patients, focusing on symptom management, pain control, and psychosocial support for patients and their families. Early integration of palliative care services has been shown to improve quality of life, reduce hospitalizations, and enhance end-of-life care for children with advanced or incurable

cancers.

### ***Survivorship Care***

With the increasing number of long-term survivors of childhood cancer, survivorship care has become a crucial component of pediatric oncology practice. Survivorship care plans, comprising surveillance protocols, health maintenance guidelines, and psychosocial support services, aim to monitor for late effects of cancer treatment, facilitate early intervention for medical and psychosocial issues, and promote healthy lifestyles among childhood cancer survivors.

### ***Psychosocial Support***

Psychosocial support services, including child life specialists, social workers, psychologists, and support groups, play an integral role in addressing the emotional, social, and developmental needs of pediatric cancer patients and their families. These supportive care measures aim to minimize the psychological impact of cancer diagnosis and treatment, promote coping skills, and foster resilience among children and adolescents facing cancer.

### ***Ongoing Research Efforts***

#### ***Pediatric Precision Oncology***

Pediatric precision oncology initiatives aim

to identify novel therapeutic targets and develop targeted therapies tailored to the molecular profiles of individual pediatric tumors. Collaborative research consortia, such as the Children's Oncology Group (COG) and the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC), facilitate multicenter clinical trials and translational research efforts to advance the field of pediatric precision oncology.

### ***Immunogenomics***

Immunogenomic studies seek to elucidate the complex interplay between the tumor microenvironment, immune system, and tumor biology in pediatric cancers. By characterizing the immune landscape of pediatric tumors, researchers aim to identify biomarkers of response to immunotherapy, uncover mechanisms of immune evasion, and develop novel immunomodulatory strategies to enhance antitumor immune responses in pediatric cancer patients.

### ***Targeted Drug Delivery***

Targeted drug delivery systems, such as nanoparticle-based drug carriers and antibody-drug conjugates, hold promise for improving the efficacy and safety of cancer therapies in pediatric patients. By enhancing drug delivery to tumor sites while minimizing systemic toxicity, targeted

drug delivery approaches aim to maximize therapeutic benefits and minimize treatment-related adverse effects in children and adolescents with cancer.

### ***Conclusion***

Advancements in the management of pediatric cancers have transformed the landscape of pediatric oncology, leading to improved outcomes and quality of life for children and adolescents with cancer. From precision medicine approaches and immunotherapies to supportive care measures and ongoing research efforts, the multidisciplinary approach to pediatric oncology continues to evolve, offering hope for the future of pediatric cancer care. Collaborative efforts among clinicians, researchers, advocacy organizations, and policymakers are essential to further advance the field and ultimately improve outcomes for children and adolescents facing cancer.



### 3- ADVANCEMENTS IN THE MANAGEMENT OF SKIN CANCERS

#### **Background**

Skin cancer is the most common type of cancer, affecting one in every five people worldwide during their lifetime. Predictions suggest that the incidence rate of skin cancer will become a major cause of mortality in the future. There are two primary categories of skin cancer: melanoma and non-melanoma skin cancer (NMSC).

#### **Melanoma Skin Cancer**

Melanoma is an aggressive, rare, and deadly type of skin cancer that originates from melanocytes. In Europe, the incidence rate of melanoma is 10–20 per 100,000 people, while in the USA, it is approximately 20–30 per 100,000. Melanoma can affect various areas of the body, typically those exposed to sunlight, such as the face and neck. Melanoma cells have a tendency to metastasize to other parts of the body, including the liver, lungs, spleen, or brain. Important risk factors for melanoma development include light skin, sunlight exposure, old age, male gender, and immunodeficiency. Melanoma can be divided into four major subtypes: superficial, nodular, acral lentiginous, and lentigo maligna.

#### **Non-Melanoma Skin Cancer**

NMSC is the most common malignancy among Caucasians, with its incidence significantly increasing by 10% per year. Annually, 2-3 million new cases are diagnosed worldwide, with similar risk factors to melanoma skin cancer. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the two main categories of NMSC, affecting the keratinocyte cells of the epidermis. BCC constitutes 75% of cases, typically occurring on sun-exposed areas, particularly the head and neck, and manifests as enlarging erythematous plaques or nodules. SCC accounts for 15-20% of NMSC cases and presents as indurated keratinizing or nonhealing ulcers on sun-exposed areas, with a higher rate of metastasis and mortality compared to BCC.

#### **Management of Skin Cancers**

Skin cancers are often diagnosed through medical history and physical examination, with lesions on sun-exposed sites exhibiting asymmetry, irregular borders, changes in color, and diameters generally exceeding 6mm. Suspicious lesions are confirmed by skin biopsy. Artificial intelligence now aids clinicians in diagnosing or making management decisions, minimizing unnecessary biopsies and overdiagnosis. Treatment options for skin cancers include surgery, chemotherapy, immunotherapy, and photodynamic therapy. Mohs micrographic

surgery (MMS) is the gold standard for high-risk BCC and SCC, involving the removal of visible lesions and surrounding tissue layers. Photodynamic therapy (PDT) targets localized cancerous sites through photochemical reactions, offering better cosmetic results and cure rates of approximately 78% at 5 years compared to surgery. Nanotechnology is emerging as a significant consideration in cancer treatment, with nanoparticles like hydrogel, liposomes, and exosomes providing controlled-release drug delivery systems to enhance drug effectiveness and patient survival while reducing adverse effects.

### **Early Detection and Diagnosis**

#### **Dermoscopy**

Dermoscopy, also known as dermatoscopy or epiluminescence microscopy, is a noninvasive diagnostic technique that allows for the magnified examination of skin lesions, enabling the visualization of morphologic features not visible to the naked eye. Recent advancements in dermoscopy technology, including polarized and non-polarized devices, digital dermoscopes, and artificial intelligence (AI)-assisted algorithms, have improved the accuracy of skin cancer diagnosis, leading to earlier detection and reduced rates of unnecessary biopsies.

#### **Reflectance Confocal Microscopy (RCM)**

Reflectance confocal microscopy (RCM) is an imaging modality that provides high-resolution, real-time visualization of cellular structures within the skin, allowing for the differentiation of benign and malignant lesions without the need for tissue biopsy. Recent studies have demonstrated the utility of RCM in improving diagnostic accuracy and guiding treatment decisions for skin cancers, particularly in cases where traditional diagnostic methods, such as histopathology, may be inconclusive or impractical.

#### **Molecular Diagnostics**

Molecular diagnostic tests, such as fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and gene expression profiling, have emerged as valuable tools for the accurate diagnosis and classification of skin cancers. These tests can detect specific genetic alterations associated with skin cancer subtypes, providing clinicians with valuable information about prognosis, treatment response, and recurrence risk. Additionally, molecular diagnostics play a crucial role in identifying actionable mutations for targeted therapy and immunotherapy in advanced or metastatic skin cancers.

## ***Surgical Interventions***

### ***Mohs Micrographic Surgery (MMS)***

Mohs micrographic surgery (MMS) is a specialized surgical technique used for the precise removal of skin cancers, particularly BCC and SCC, while preserving surrounding healthy tissue. Recent advancements in MMS technology, including frozen section histopathology and digital imaging systems, have improved procedural efficiency, accuracy, and cosmesis, leading to higher cure rates and reduced rates of recurrence in patients with high-risk or recurrent skin cancers.

### ***Laser Therapy***

Laser therapy has emerged as a minimally invasive treatment modality for select cases of superficial skin cancers, including BCC and SCC, as well as precancerous lesions such as actinic keratoses. Recent advancements in laser technology, such as fractional laser resurfacing, photodynamic therapy (PDT), and ablative laser therapy, have expanded the utility of laser therapy in the management of skin cancers, offering improved cosmetic outcomes, shorter recovery times, and reduced treatment-related morbidity compared to traditional surgical interventions.

### ***Robotic Surgery***

Robotic surgery, facilitated by robotic-assisted surgical systems such as the da Vinci Surgical System, has gained traction in the management of skin cancers, particularly in complex or challenging anatomical locations. Robotic surgery offers several advantages over traditional surgical approaches, including enhanced precision, dexterity, and visualization, as well as reduced postoperative pain, scarring, and recovery times. Recent studies have demonstrated the safety and efficacy of robotic surgery for the resection of skin cancers, with promising outcomes in terms of oncologic control and cosmesis.

## ***Targeted Therapies***

### ***Hedgehog Pathway Inhibitors***

The hedgehog signaling pathway plays a critical role in the pathogenesis of BCC, with aberrant activation of this pathway implicated in the development and progression of BCC tumors. Hedgehog pathway inhibitors, such as vismodegib and sonidegib, have been approved for the treatment of locally advanced and metastatic BCC, offering a targeted therapeutic approach for patients who are not candidates for surgery or radiation therapy. Recent clinical trials have demonstrated the efficacy of hedgehog pathway inhibitors in achieving durable responses and delaying disease progression in patients with advanced BCC.

### 3.2 Epidermal Growth Factor Receptor (EGFR) Inhibitors:

EGFR inhibitors, such as cetuximab and erlotinib, have shown promise in the treatment of advanced SCC, particularly in cases where conventional therapies have failed or disease recurrence has occurred. By targeting the EGFR signaling pathway, these agents inhibit tumor cell proliferation, angiogenesis, and metastasis, leading to tumor regression and improved survival outcomes in select patients. Recent studies have explored the use of EGFR inhibitors in combination with other targeted agents or immunotherapies to enhance treatment efficacy and overcome resistance mechanisms in advanced SCC.

## ***Immunotherapies***

### ***Immune Checkpoint Inhibitors***

Immune checkpoint inhibitors, such as pembrolizumab, nivolumab, and ipilimumab, have revolutionized the treatment landscape for advanced melanoma, offering durable responses and long-term survival benefits in a subset of patients. By blocking inhibitory signals on T cells, immune checkpoint inhibitors unleash the immune system's ability to recognize and destroy tumor cells, leading to tumor regression and improved outcomes in patients with metastatic melanoma. Recent advancements in biomarker

testing, including programmed death-ligand 1 (PD-L1) expression and tumor mutational burden (TMB) analysis, have facilitated patient selection and treatment optimization with immune checkpoint inhibitors.

### ***Adoptive Cell Therapy***

Adoptive cell therapy (ACT), particularly chimeric antigen receptor (CAR) T-cell therapy, holds promise as a novel immunotherapeutic approach for the treatment of advanced melanoma and other skin cancers. By genetically engineering T cells to express tumor-specific antigen receptors, CAR T-cell therapy enables targeted recognition and elimination of tumor cells, leading to durable responses and potential cures in select patients. Ongoing clinical trials are evaluating the safety and efficacy of CAR T-cell therapy in patients with refractory or relapsed skin cancers, with promising early results.

### ***Supportive Care Measures***

#### ***Targeted Skin Care***

Targeted skin care interventions, including topical agents, moisturizers, and wound dressings, play a crucial role in the supportive care of patients undergoing treatment for skin cancers. These interventions aim to minimize treatment-related side effects, such as skin irritation, dryness, and photosensitivity, while promoting skin healing,

hydration, and protection. Recent advancements in skincare formulations, such as ceramide-based emollients, silicone gel sheets, and hydrogel dressings, offer improved efficacy and tolerability for patients with skin cancers.

### ***Psychosocial Support***

Psychosocial support services, including counseling, support groups, and mindfulness-based interventions, are integral components of comprehensive cancer care for patients with skin cancers. These services address the emotional, social, and psychological needs of patients and their families, helping them cope with the challenges of diagnosis, treatment, and survivorship. Recent advancements in telehealth and digital health platforms have expanded access to psychosocial support services, allowing patients to receive personalized care remotely and participate in virtual support communities.

### ***Conclusion***

Advancements in the management of skin cancers have transformed the landscape of dermatologic oncology, offering patients more personalized, effective, and tolerable treatment options. From early detection and diagnosis to targeted therapies, immunotherapies, and supportive care measures, multidisciplinary approaches to skin cancer management continue to evolve, driven by ongoing research efforts, technological

innovations, and collaborative partnerships across the healthcare continuum. Moving forward, continued investment in research, education, and patient-centered care is essential to further improve outcomes and quality of life for individuals affected by skin cancers worldwide.

## **4- ADVANCEMENTS IN THE MANAGEMENT OF BREAST AND LUNG CANCERS**

### ***Background***

Breast cancer is diagnosed as the most common non-skin tumor in women and remains the second deadliest cancer among women worldwide. It has a high incidence and mortality compared to other cancers. Breast cancer cells originate from breast tissue, with tumors occurring frequently in women, though nearly one in a thousand men will experience breast tumors in their lifetime. Early diagnosis of breast tumors is an essential factor for good treatment and decreasing mortality; however, early breast tumor patients can be clinically asymptomatic, and breast tumors can evolve silently.

Methods of breast screening include breast self-exam, clinical exam, breast tissue biopsy, and imaging such as mammography, magnetic resonance imaging (MRI), and ultrasonography. Breast cancer treatment includes surgery, radiation therapy, and systemic therapies such as hormone therapy, targeted therapy, and chemotherapy. Generally, types of breast cancer include invasive and non-invasive breast cancer, with non-invasive breast cancer divided into

ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). Risk factors for breast cancer include genetic and family history, gender, age, obesity, histologic risk factors, and exogenous hormone use including estrogen and progesterone therapy.

As described in the text, breast cancer is one of the malignant tumors that make women vulnerable. Each year sees new breast cancer cases worldwide, and today there are many methods for screening and treating breast cancer. Research is ongoing to develop powerful evaluation, management, and treatment strategies.

Bronchogenic carcinoma, or lung cancer, is one of the leading causes of mortality among women and men worldwide. Lung cancer has a high incidence and mortality, with approximately 225,000 new cases and 160,000 deaths annually in the United States alone. Although the pathophysiology of bronchogenic carcinoma is not completely understood and is complex, it is estimated that approximately 80% of lung cancer deaths are attributable to smoking and secondhand smoke. Other risk factors include exposure to air pollution, radon, familial lung cancer history, age, chronic obstructive pulmonary diseases, and race and ethnicity.

Several anticancer strategies are available for the evaluation, diagnosis, and treatment of lung cancer, including radiological staging (CT and PET scan), invasive staging (pathologic confirmation

of malignancy, evaluation of tumor markers), chemotherapy, surgery, radiation, and treatment with systemic therapy. There is a near 5-year relative survival rate from the first diagnosis of lung cancer. However, lung cancer is an essential public health issue and one of the most threatening types of neoplasm; therefore, it is urgent to develop new effective strategies to manage lung cancer.

### **Risk Factors**

Risk factors for breast cancer encompass modifiable and non-modifiable elements. Modifiable factors include alcohol consumption, tobacco smoking, lack of physical activity, abortion, and late-night eating, while non-modifiable ones include age and gender. Primary risk factors include female sex and older age, alongside early menarche, menopausal status, nulliparity, late pregnancy, lack of breastfeeding, oral contraceptives, increased estrogen levels, radiation exposure, cancer history, vitamin D deficiency, lack of childbearing, obesity, and diabetes. A quarter of breast cancers are preventable through lifestyle modifications, while susceptibility genes contribute to a 5–10% increased risk across generations.

Elevated estrogen levels, combined with a high-fat and low-fiber diet, stimulate breast tissue, thereby increasing cancer risk. Breast cancer incidence rises after the age of 20, although cases before this

age are rare, and the disease is twice as common in women aged 50 compared to those aged 40. Environmental factors contribute to 90-95% of breast cancer cases, with prognosis and mortality rates varying based on age, stage, type, axillary lymph node status, HER2 status, histological features, hormone receptor status, and treatment options. Early diagnosis significantly impacts survival.

### ***Incidence***

Epidemiological studies indicate a higher incidence of breast cancer in Asian women compared to those in the United States, particularly prevalent in developing countries, northern areas of Pakistan, and densely populated South Asian regions. Approximately 50% of breast cancer cases and 60% of deaths occur in these regions. The risk of breast cancer is lower in women with many children compared to those with fewer children. While women are predominantly affected, men with breast tissue can also develop the disease. Obesity increases breast cancer risk, although menopause reduces it, as estrogen production ceases, but fatty tissue in obese women can still provide estrogen, thereby increasing cancer risk.

### ***Anatomy of the Breast***

The breast is situated on the anterior thoracic wall and comprises adipose tissue. Female breasts

consist of 12-20 lactiferous units called lobes, each subdivided into lobules that terminate in mammary glands capable of milk production. These lobes and lobules are connected by thin tubes called milk ducts. The breasts lack muscle tissue, with the pectoralis major muscles covering the ribs. Breast tissue also contains lymph vessels and blood vessels, with lymph nodes located in the armpits, draining the breast tissues. Breasts are sensitive to hormonal changes; for instance, during pregnancy, increased estrogen and progesterone levels inhibit milk production, while postpartum prolactin secretion affects mammary glands and uterus contractions.

### ***History and Physical Examination***

History and physical examination aim to investigate cancer in the target population, including symptoms like weight loss, breast or armpit lumps, skin dimpling, swollen lymph nodes, insomnia, breast pain, bone pain, tiredness, and nipple discharge. Other factors include early menarche, menopausal condition, pregnancy timing, hormone therapy, oral contraceptives use, cancer history, vitamin D deficiency, childbirth, physical activity, obesity, and diabetes. Physical examination includes breast examination, neck, collarbone, and armpit assessments.

### ***Diagnosis***



### ***Mammography***

Considered the gold standard for breast cancer detection, mammography detects most non-invasive lesions but cannot distinguish between simple breast cysts and breast cancer, missing up to 10-15% of all breast cancer cases.

### ***Ultrasound Breast Imaging***

Ultrasound breast imaging in high-risk women helps distinguish between simple breast cysts and breast cancer detected by physical examination. It aids in diagnosing malignant tumors at early stages and monitoring cancer during treatment. Breast ultrasound, alone or combined with mammography, is a common tool for diagnosing and managing invasive breast cancers.

### ***Single Photon Emission Computerized Tomography (SPECT)***

SPECT is a fine method for diagnosing breast cancer at early stages and evaluating therapy for metastatic cancers. It is a safe method suitable for the entire body.

### ***Positron Emission Tomography (PET/CT)***

PET/CT is a comparatively safe and powerful method for detecting breast cancer, evaluating treatment responses, managing breast cancer, and

predicting survival.

### ***Breast MRI***

Breast MRI is applied in women at very high risk and for assessing disease extent, therapy response, lymph nodes, primary occult tumors, and suspicious discharge.

### ***Nuclear Medicine***

Molecular imaging is a noninvasive method for measuring biological processes at the molecular, cellular, and tissue levels. Tumor markers are measured in all stages for detecting and screening, predicting metastasis, and guiding treatment. CA-15-3 antigen is particularly valuable in breast cancer patients. The levels of CA 15-3 may increase in a few non-cancerous conditions as well as in patients with hepatitis and benign breast conditions. Similarly, Ca 27.29 levels increase in breast cancer, other cancers, and certain non-cancerous disorders. Estrogen and progesterone receptors are increased in the majority of breast cancers.

### ***Immunohistochemical Markers***

Immunohistochemical markers are used to classify breast cancer, guide treatment decisions, and manage the disease.

### ***Immunohistochemistry***

Immunohistochemistry is an essential tool

in diagnostic pathology laboratories used for diagnosing primary breast carcinomas, metastatic carcinomas, non-mammary metastases, patient staging, treatment allocation, and prognosis.

## **Treatment**

### **Surgical Intervention**

The surgical treatment of breast cancer remains generally the main and most effective therapeutic option for early-stage disease. Depending on the different type, size, and stage of the tumor, surgery includes two main methods: Breast-conserving surgery (BCS) and mastectomy.

Breast-conserving surgery comprises lumpectomy and quadrantectomy. In recent decades, the survival rate of BCS with radiotherapy has shown equivalence with mastectomy in managing breast cancer with Stage I or II. Thus, BCS has become the gold standard for most patients with the intention of preserving breast tissue, achieving aesthetic outcomes, and minimizing the risk of relapse.

Mastectomy is a common approach used in patients with large tumors, late-stage breast cancer, and involves the removal of the entire breast. Several types of this procedure exist, including simple mastectomy (most common type), Skin Sparing Mastectomy, nipple-areolar sparing mastectomy, modified radical mastectomy, and Radical Mastectomy. Compared to BCT, patients who undergo mastectomies

experience higher physical and emotional effects, including shoulder restrictions, breast asymmetry leading to spinal deformity (like scoliosis), depression, and anxiety, which reduce the quality of life. Oncoplastic techniques, which incorporate breast conservative surgery and plastic reconstructive techniques, optimize cosmetic outcomes, symmetry, and the quality of life. Oncoplastic surgery can be categorized into two groups of volume replacement and volume displacement techniques.

### **Chemotherapy**

Neoadjuvant chemotherapy (NAC) has been considered the primary systematic management that attacks all growing cells. These systemic drugs are used to kill cancer cells or suppress tumor growth. The purpose of NAC is to reduce tumor size in locally advanced breast cancer, non-metastatic inoperable tumors, or mid-stage breast cancer before surgery and transform them into operable tumors. On the other hand, adjuvant chemotherapy was introduced to treat breast cancers with latent micrometastases after surgery and improve overall survival.

### **Radiotherapy**

Radiation therapy (RT) is performed after breast-conserving surgery to improve overall survival and decrease locoregional recurrence. Adjuvant radiotherapy is used for all cancer

types but is favorable in patients with early-stage breast cancer, metastatic cases, or locally advanced breast cancer (LABC). According to the varying types of surgery, breast size, and pathology reports, modern radiotherapy techniques were introduced, including intensity-modulated radiotherapy, 3D conformal RT, and volumetric modulated arc therapy (VMAT). The fractionation size of radiation, which includes conventional fractionated and hypofractionated RT, is one of the factors that affect the outcome of breast cancer treatment. Conventional adjuvant radiotherapy uses a 50 Gy fractionation consisting of 25 fractions over 5 weeks. This plan causes inconvenience due to the long overall duration and high medical cost.

### ***Endocrine Therapy***

Luminal cancer, which expresses the estrogen receptor (ER positive) and the progesterone receptor (PR positive), represents approximately 75% of breast cancer cases. Hormone therapy still remains the main systemic strategy for patients with HR-positive invasive breast cancer, mostly used in combination based on various mechanisms. The most common regimens of hormone therapy include aromatase inhibitors, selective modulators estrogen receptor degraders (such as fulvestrant), and selective estrogen receptor modulators (such as tamoxifen, raloxifene, and toremifene).

4.1 SERMs, depending on the target site, activate two main isoforms of the estrogen receptor by producing different tissue responses, acting as antagonists for ER $\beta$  in breast tissue and inhibiting their activity. However, they display as agonists for ER $\alpha$  in tissues including the cardiovascular system, liver, bone, GI, and CNS, mimicking estrogen's activity.

4.2 Aromatase inhibitors inhibit estrogen synthesis by targeting the aromatase enzyme found in tissues like the uterus, breast, ovary, placenta, and adipose tissue, and can be classified into steroidal and nonsteroidal subtypes. In postmenopausal patients, aromatase inhibitors have become the more effective endocrine therapy compared to tamoxifen.

### ***Anti-HER2 Therapy***

The overexpression of HER2 oncogenes occurs in approximately 20% of invasive breast cancers, which is associated with poor patient outcomes, a higher rate of recurrence, and unfavorable prognoses compared to HR-positive/HER2-negative breast cancers. Anti-HER2 therapies include Antibodies Targeting HER2 (trastuzumab, pertuzumab), tyrosine kinase inhibitors (lapatinib), and antibody-drug conjugates (trastuzumab-emtansine). The introduction of anti-HER2 agents has dramatically improved survival and prognosis for patients with HER2+ breast cancer in early stages.

### ***PARP Inhibitors***

The development of targeted therapies plays a key role in the treatment of triple-negative breast cancer, which does not express receptors (HER-2 negative, ER negative, PR negative) for endocrine therapy. PARP proteins, notably PARP1 and PARP2, are pivotal components for the function of the base excision repair pathway, which plays a crucial role in the recognition and repair of DNA damage in single-strand breaks (SSB). PARP inhibitors including Olaparib, rucaparib, Talazoparib, and Veliparib act as catalytic inhibitors of PARP proteins, interfering with the BER pathway and ultimately leading to the death of tumor cells.

## **5- ADVANCEMENTS IN THE MANAGEMENT OF ORAL CANCERS**

### ***Background***

Oral cancer, which includes cancers of the lips, tongue, cheeks, floor of the mouth, hard and soft palate, sinuses, and pharynx, poses a significant global health burden. Despite advancements in early detection and treatment, oral cancers continue to have high morbidity and mortality rates. However, recent years have witnessed remarkable progress in the management of oral cancers, driven by advancements in diagnostic techniques, surgical interventions, radiotherapy, chemotherapy, targeted therapies, immunotherapies, and supportive care measures. This comprehensive review explores the latest advancements in the management of oral cancers, focusing on key developments in each domain and their impact on patient outcomes and quality of life.

### ***Early Detection and Diagnosis***

#### ***Oral Cancer Screening Programs***

Early detection of oral cancers plays a crucial role in improving patient outcomes and survival rates. Oral cancer screening programs, which involve visual and tactile examination of the

oral cavity by healthcare professionals, aim to identify suspicious lesions at an early stage when they are more amenable to curative treatment. Recent advancements in oral cancer screening include the integration of adjunctive diagnostic tools such as toluidine blue staining, brush cytology, autofluorescence imaging, and salivary biomarker analysis, which enhance the sensitivity and specificity of screening methods, leading to improved detection rates and reduced false-positive results.

### ***Optical Imaging Technologies***

Optical imaging technologies, such as narrow-band imaging (NBI), fluorescence imaging, and optical coherence tomography (OCT), enable real-time visualization of tissue architecture and vascular patterns within the oral mucosa, aiding in the early detection and characterization of oral cancer lesions. These noninvasive imaging modalities provide valuable information about tissue morphology, vascularity, and cellular changes, allowing clinicians to differentiate between benign and malignant lesions and guide biopsy decisions. Recent advancements in optical imaging technology have led to the development of portable and affordable devices that can be used in primary care settings for point-of-care oral cancer screening and surveillance.

### ***Liquid Biopsy***

Liquid biopsy, which involves the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and other biomarkers in peripheral blood or saliva, has emerged as a promising diagnostic tool for oral cancers. Liquid biopsy offers several advantages over traditional tissue biopsy, including minimally invasive sampling, real-time monitoring of disease progression, and the detection of molecular alterations associated with treatment response and resistance. Recent studies have demonstrated the utility of liquid biopsy in identifying actionable mutations, monitoring treatment response, and detecting minimal residual disease in patients with oral cancers, highlighting its potential as a noninvasive diagnostic and prognostic tool.

### ***Surgical Interventions***

#### ***Transoral Robotic Surgery (TORS)***

Transoral robotic surgery (TORS) is a minimally invasive surgical technique that uses robotic-assisted technology to access and resect tumors within the oral cavity and oropharynx. TORS offers several advantages over traditional open surgery, including improved visualization, precision, and access to anatomically challenging sites, as well as reduced postoperative pain, hospital stay, and recovery time. Recent advancements in TORS technology, including the

development of novel robotic platforms and instrumentation, have expanded the indications for TORS to include complex and recurrent oral cancers, leading to improved oncologic outcomes and functional preservation in select patients.

#### ***Microvascular Reconstruction***

Microvascular reconstruction, also known as free flap surgery, is a specialized surgical technique used for the reconstruction of defects following tumor resection in the oral cavity and oropharynx. Microvascular reconstruction involves the transfer of tissue from distant donor sites, such as the forearm, thigh, or abdomen, to the surgical site using microsurgical techniques to restore form and function. Recent advancements in microvascular reconstruction techniques, including perforator flap surgery, virtual surgical planning, and intraoperative imaging, have improved the accuracy, efficiency, and outcomes of reconstructive procedures for oral cancers, leading to enhanced aesthetic and functional outcomes and reduced donor site morbidity.

#### ***Sentinel Lymph Node Biopsy (SLNB)***

Sentinel lymph node biopsy (SLNB) is a minimally invasive surgical technique used to assess the status of regional lymph nodes in patients with oral cancers. SLNB involves the injection of a tracer dye or radioactive substance into the primary

tumor site to identify the sentinel lymph node, which is the first lymph node to receive drainage from the tumor site. Recent advancements in SLNB technology, including the use of indocyanine green (ICG) fluorescence imaging and intraoperative navigation systems, have improved the accuracy and reliability of lymph node mapping, leading to reduced false-negative rates and unnecessary neck dissections in patients with oral cancers.

### ***Radiotherapy***

#### ***Intensity-Modulated Radiation Therapy (IMRT)***

Intensity-modulated radiation therapy (IMRT) is a highly precise radiotherapy technique that delivers high doses of radiation to the tumor while sparing adjacent normal tissues. IMRT allows for customized dose distributions and modulation of radiation beams based on tumor size, shape, and location, resulting in improved tumor control and reduced treatment-related toxicity in patients with oral cancers. Recent advancements in IMRT technology, such as volumetric modulated arc therapy (VMAT) and proton beam therapy, have further enhanced the therapeutic ratio of radiotherapy for oral cancers, offering superior target coverage and organ sparing while minimizing acute and late side effects.

### ***Stereotactic Body Radiation Therapy (SBRT)***

Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), is a hypofractionated radiotherapy technique that delivers high doses of radiation to the tumor in a limited number of treatment sessions. SBRT exploits advanced imaging and immobilization techniques to precisely target the tumor while minimizing radiation exposure to surrounding normal tissues. Recent studies have demonstrated the efficacy and safety of SBRT in the definitive treatment of early-stage oral cancers, as well as in the management of locally recurrent or oligometastatic disease, leading to high rates of tumor control and favorable treatment outcomes with minimal toxicity.

### ***Chemotherapy***

#### ***Targeted Therapies***

Targeted therapies, such as epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, and mammalian target of rapamycin (mTOR) inhibitors, have shown promise in the treatment of advanced or recurrent oral cancers. By targeting specific molecular pathways involved in tumor growth, angiogenesis, and metastasis, targeted therapies disrupt tumor cell proliferation

and survival, leading to tumor regression and improved patient outcomes. Recent advancements in targeted therapy include the development of novel agents and combination regimens, as well as the identification of predictive biomarkers to guide patient selection and treatment response.

### ***Immunotherapies***

Immunotherapies, such as immune checkpoint inhibitors and adoptive cell therapies, have revolutionized the treatment of oral cancers by harnessing the immune system to recognize and eliminate tumor cells. Immune checkpoint inhibitors, which block inhibitory signals that suppress antitumor immune responses, have demonstrated durable responses and improved survival outcomes in patients with advanced or metastatic oral cancers. Recent advancements in immunotherapy include the development of novel checkpoint inhibitors, combination immunotherapy regimens, and predictive biomarkers, as well as the optimization of treatment strategies to overcome resistance mechanisms and enhance response rates.

### ***Supportive Care Measures***

#### ***Oral Mucositis Management***

Oral mucositis is a common side effect of cancer treatment, particularly radiotherapy and chemotherapy, characterized by inflammation

and ulceration of the oral mucosa. Recent advancements in oral mucositis management include the use of preventive strategies, such as cryotherapy, low-level laser therapy, and mucosal coating agents, to reduce the severity and duration of mucositis and improve patient comfort and quality of life during treatment. Supportive care measures, such as pain management, nutritional support, and oral hygiene interventions, are essential components of comprehensive supportive care for patients with oral cancers, aimed at minimizing treatment-related morbidity and optimizing treatment outcomes.

### ***Pain Management***

Pain is a common symptom experienced by patients with oral cancers, resulting from tumor invasion, nerve compression, mucosal ulceration, and treatment-related side effects. Recent advancements in pain management include the use of multimodal analgesic regimens, including opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), adjuvant medications, and interventional techniques, to achieve optimal pain control and improve patient comfort and quality of life. Palliative care services, such as hospice care and supportive care teams, play a crucial role in addressing the complex physical, psychological, social, and spiritual needs of patients with advanced or incurable oral cancers, ensuring compassionate and holistic care



throughout the disease trajectory.

### **Conclusion**

Advancements in the management of oral cancers have transformed the landscape of head and neck oncology, offering patients more personalized, effective, and multidisciplinary treatment options. From early detection and diagnosis to surgical interventions, radiotherapy, chemotherapy, targeted therapies, immunotherapies, and supportive care measures, the integration of innovative technologies, evidence-based practices, and collaborative approaches has led to improved outcomes and quality of life for individuals affected by oral cancers worldwide. Moving forward, continued investment in research, education, and patient-centered care is essential to further enhance our understanding of oral cancers, optimize treatment strategies, and improve long-term survival and survivorship outcomes for patients living with this challenging disease.

## 6- ADVANCEMENTS IN THE MANAGEMENT OF HEAD AND NECK CANCERS

### *Background*

Head and neck squamous carcinoma (HNSCC) is a significant global health concern, constituting 4% of all malignancies and resulting in approximately 67,000 new cases annually. The standard treatment modalities for early-stage HNSCC involve surgery and definitive radiotherapy (RT), both demonstrating comparable efficacy in achieving local control and ensuring survival. However, challenges persist, with nearly 40% of patients experiencing recurrence within five years of definitive treatment, and survivors facing a substantial 15–40% risk of developing secondary primary tumors.

To address recurrent cases, reirradiation has gained acceptance, particularly with the advent of highly conformal techniques such as intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), image-guided radiotherapy (IGRT), and protons or heavy ions. Reirradiation serves as a viable alternative when complete surgical resection is not feasible due to tumor extension to critical organs or when a patient's

condition is unsuitable for surgery. However, a major drawback of reirradiation lies in the potential for acute or late toxicity, with dosage limitations required to protect surrounding organs at risk (OARs).

A systematic review delves into the impact of time intervals between diagnosis and treatment on various outcomes in patients with oral, pharyngeal, and laryngeal cancers. The comprehensive analysis aims to provide insights into the effects on oncologic outcomes, functional outcomes, and quality of life (QoL). Timely initiation of treatment is crucial, as delays may negatively influence tumor stage at diagnosis and subsequent survival outcomes. The review acknowledges the heterogeneous nature of head and neck cancers and emphasizes the need for a nuanced understanding to tailor interventions based on the specific characteristics and risks associated with each subtype.

The multifaceted nature of head and neck cancers is evident, with distinct risk factors associated with different subtypes. Smoking, excessive drinking, and human papillomavirus (HPV) infection are well-established risk factors, with a notable rise in the incidence of HPV-related HNSCC. Despite substantial therapeutic developments, the 5-year survival rate for patients with HNSCC remains dismal. Late diagnosis, recurrent metastasis, relapse, and resistance to therapies contribute to this challenge. Surgery and

radiotherapy are foundational treatment options for initial-stage HNSCC patients, but they come with significant morbidity and poor prognosis.

The scientific community's research efforts are focused on understanding HNSCC biology and immunobiology to identify predictive and prognostic biomarkers, ultimately aiming to develop more effective targeted therapies with less toxicity and higher specificity. In conclusion, this comprehensive overview integrates insights from various perspectives on the management of head and neck cancers. From advancements in treatment modalities to challenges in recurrent cases, the impact of time intervals on outcomes, and ongoing efforts to enhance therapeutic approaches, the collective body of research contributes significantly to the evolving field. As the scientific community navigates the complexities of HNSCC, the ultimate goal remains to improve outcomes and enhance the quality of life for individuals facing this challenging disease. HNC rank among the ten most prevalent cancers worldwide, with squamous cell carcinoma (SCC) comprising over 90% of malignancies in this region. Histopathologically, other head and neck tumors encompass adenocarcinoma, sarcoma, anaplastic carcinoma, plasmacytoma, lymphoma, and malignant melanoma. Standard treatment modalities for HNC comprise surgery, radiotherapy, and systemic therapy. Despite numerous advancements in treating patients with

this cancer, the 5-year survival rate of HNC patients has seen minimal improvement in recent decades. Major risk factors for head and neck cancer include smoking, alcohol consumption, human papillomavirus (HPV) and Epstein-Barr virus (EBV) infections, and genetic mutations. The management of this cancer can be explored in two areas.

The first area involves screening and early diagnosis of the cancer. Due to limited treatment options for advanced and recurrent malignancies, early detection of this cancer can significantly impact patient outcomes. Employing non-invasive methods to detect infections, discovering diagnostic biomarkers for cancer detection, examining blood changes, and utilizing liquid biopsy to evaluate and analyze biomarkers such as exosomes, circulating cancer cells, and circulating tumor DNA play crucial roles in predicting, prognosticating, and monitoring treatment response.

The second area of HNC cancer management pertains to treatment management. Despite significant progress in the field of cancer treatment, this cancer still lacks a complete cure due to individual variations in treatment response, necessitating new treatment goals. Adopting a personalized treatment approach for each patient, based on the heterogeneous nature of HNC malignancies, is essential in this context. Predicting clinical outcomes involves

understanding tumor behaviors and the genetic and molecular characteristics of tumor cells through a multi-OMIC approach encompassing genomics, epigenetics, metabolomics, proteomics, and radiogenomics. The analysis of these factors aids in planning to adjust the therapeutic dose for each person and personalize the treatment. As a result, "precision medicine" not only predicts therapeutic effects by providing personalized treatment based on genetic, clinical, and lifestyle information but also enhances efficiency, reduces unnecessary side effects, and prevents diseases.

Due to the heterogeneous nature of HNC tumors, the development and expansion of methods for identifying and isolating them from other cells in the tumor microenvironment lead to differentiated treatment approaches. Platforms such as 'single-cell separation' and 'single-cell analysis' analyze tumor heterogeneity and can be instrumental in developing therapeutic strategies. Cancers affecting the head and neck encompass a diverse group of highly aggressive diseases originating from areas such as the oral cavity, oropharynx, nasopharynx, hypopharynx, and larynx. Each subtype within this category exhibits unique characteristics in terms of therapy, etiology, and epidemiological trends. These malignancies profoundly impact overall health, mental well-being, quality of life, employment, appearance, family dynamics, and social interactions. Understanding the disease's

development and presentation aids in treatment decisions, symptom analysis, and clarification of treatment side effects.

HNSCC is the sixth most common cancer, affecting the upper aerodigestive tract sites and significantly threatening patients' quality of life. HNSCC arises from the complex interaction of genetic factors and environmental influences, with alcohol consumption and tobacco smoking being the primary risk factors implicated in most cases affecting the oral cavity, larynx, and pharynx.

Despite considerable advancements in diagnosis and treatment over recent decades, mortality rates for head and neck cancers have seen limited improvement, largely due to late-stage diagnoses. Treatment modalities include surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapy, often administered in combination. While surgery remains the standard treatment for early oral cavity and larynx cancers, concurrent chemoradiation or intensity-modulated radiation therapy is recommended for other early head and neck cancers.

Conventional diagnosis relies on clinical, radiographical, and histopathological evaluations, which can be prone to errors and time-consuming. Consequently, efforts have been made to explore alternative strategies for early detection, although challenges persist due to indistinctive diagnostic features and vague histories.

The emergence of deep learning and machine learning techniques has shown promising results in prognostication for head and neck cancer. Machine learning, a subset of artificial intelligence, leverages computational methods and algorithms to make predictions based on histological information. Deep learning, a subfield of machine learning, constructs neural networks with multiple hidden layers, enabling more accurate and efficient predictions as dataset sizes increase.

These methods utilize digital image processing and analysis to delineate clinical features or classify labels, a process known as segmentation and classification, respectively. Radiographs, computed tomography (CT), ultrasound (US), nuclear medicine imaging, and positron emission tomography (PET) provide essential data sources for these analyses.

The popularity of artificial intelligence and its subfields has surged due to their ability to deliver highly accurate predictions. Moreover, AI-based solutions have significantly accelerated the treatment planning process for head and neck cancer patients.

### ***Early Detection and Diagnosis***

#### ***Screening Programs***

Early detection of head and neck cancers is critical for improving patient outcomes and survival

rates. Screening programs, which involve visual and physical examination of the oral cavity, oropharynx, and neck by healthcare professionals, aim to identify suspicious lesions at an early stage when they are more amenable to curative treatment. Recent advancements in screening programs include the integration of adjunctive diagnostic tools such as autofluorescence imaging, narrow-band imaging (NBI), and salivary biomarker analysis, which enhance the sensitivity and specificity of screening methods, leading to improved detection rates and reduced false-positive results.

#### ***Molecular Imaging***

Molecular imaging techniques, such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and molecular MRI, enable noninvasive visualization and characterization of tumor biology and microenvironment in head and neck cancers. By targeting specific molecular pathways and biomarkers associated with tumor growth, angiogenesis, and metastasis, molecular imaging provides valuable insights into tumor behavior, treatment response, and prognosis. Recent advancements in molecular imaging technology have led to the development of novel radiotracers and imaging agents, as well as the integration of hybrid imaging modalities, such as PET/CT and PET/MRI, which offer improved sensitivity and

specificity for detecting primary tumors, regional lymph node metastases, and distant metastatic sites.

### ***Liquid Biopsy***

Liquid biopsy, which involves the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and other biomarkers in peripheral blood or saliva, has emerged as a promising diagnostic tool for head and neck cancers. Liquid biopsy offers several advantages over traditional tissue biopsy, including minimally invasive sampling, real-time monitoring of disease progression, and the detection of molecular alterations associated with treatment response and resistance. Recent studies have demonstrated the utility of liquid biopsy in identifying actionable mutations, monitoring treatment response, and detecting minimal residual disease in patients with head and neck cancers, highlighting its potential as a noninvasive diagnostic and prognostic tool.

### ***Surgical Interventions***

#### ***Transoral Robotic Surgery (TORS)***

Transoral robotic surgery (TORS) is a minimally invasive surgical technique that uses robotic-assisted technology to access and resect tumors within the oral cavity, oropharynx, and larynx.

TORS offers several advantages over traditional open surgery, including improved visualization, precision, and access to anatomically challenging sites, as well as reduced postoperative pain, hospital stay, and recovery time. Recent advancements in TORS technology, including the development of novel robotic platforms and instrumentation, have expanded the indications for TORS to include complex and recurrent head and neck cancers, leading to improved oncologic outcomes and functional preservation in select patients.

#### ***Microvascular Reconstruction***

Microvascular reconstruction, also known as free flap surgery, is a specialized surgical technique used for the reconstruction of defects following tumor resection in the head and neck region. Microvascular reconstruction involves the transfer of tissue from distant donor sites, such as the forearm, thigh, or abdomen, to the surgical site using microsurgical techniques to restore form and function. Recent advancements in microvascular reconstruction techniques, including perforator flap surgery, virtual surgical planning, and intraoperative imaging, have improved the accuracy, efficiency, and outcomes of reconstructive procedures for head and neck cancers, leading to enhanced aesthetic and functional outcomes and reduced donor site morbidity.

### ***Robotic-Assisted Neck Dissection***

Robotic-assisted neck dissection is a minimally invasive surgical technique used for the removal of regional lymph nodes in patients with head and neck cancers. Robotic-assisted neck dissection offers several advantages over traditional open surgery, including improved visualization, precision, and access to deep-seated lymph nodes, as well as reduced postoperative pain, scar formation, and recovery time. Recent advancements in robotic-assisted neck dissection technology, including the development of novel robotic platforms and instrumentation, have expanded the indications for robotic neck dissection to include selective and comprehensive neck dissections, leading to improved oncologic outcomes and reduced morbidity in patients with head and neck cancers.

### ***Radiotherapy***

#### ***Intensity-Modulated Radiation Therapy (IMRT)***

Intensity-modulated radiation therapy (IMRT) is a highly precise radiotherapy technique that delivers high doses of radiation to the tumor while sparing adjacent normal tissues. IMRT allows for the modulation of radiation intensity and beam shape to conform to the shape of the tumor, thereby maximizing tumor control

and minimizing radiation-related toxicity. Recent advancements in IMRT technology, including the integration of image-guided radiotherapy (IGRT) and adaptive radiotherapy (ART), have further improved the accuracy and efficacy of radiation delivery for head and neck cancers, leading to enhanced tumor control rates and reduced treatment-related side effects.

### ***Proton Therapy***

Proton therapy is an advanced form of external beam radiotherapy that uses protons, instead of traditional photons, to deliver radiation to the tumor. Proton therapy offers several advantages over conventional radiotherapy, including reduced dose to surrounding normal tissues, increased tumor control rates, and decreased treatment-related toxicity. Recent advancements in proton therapy technology, including pencil beam scanning and intensity-modulated proton therapy (IMPT), have improved the precision and efficiency of radiation delivery for head and neck cancers, leading to superior clinical outcomes and improved quality of life for patients.

### ***Stereotactic Body Radiotherapy (SBRT)***

Stereotactic body radiotherapy (SBRT) is a highly conformal radiotherapy technique that delivers high doses of radiation to the tumor with extreme precision. SBRT is typically used for the treatment

of small, well-defined tumors, such as recurrent or oligometastatic lesions in the head and neck region. Recent advancements in SBRT technology, including the use of image-guidance systems and motion management techniques, have improved the accuracy and safety of radiation delivery, leading to high rates of local tumor control and minimal treatment-related toxicity in patients with head and neck cancers.

### ***Chemotherapy***

#### ***Targeted Therapies***

Targeted therapies, which selectively inhibit specific molecular targets involved in tumor growth and progression, have revolutionized the treatment of head and neck cancers. Targeted therapies include small molecule inhibitors, monoclonal antibodies, and immune checkpoint inhibitors, which target key signaling pathways such as the epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and programmed cell death protein 1 (PD-1) pathway. Recent advancements in targeted therapy include the development of novel agents, combination therapy regimens, and predictive biomarkers to guide patient selection and treatment response.

#### ***Immunotherapies***

Immunotherapies, such as immune checkpoint

inhibitors and adoptive cell therapies, have revolutionized the treatment of head and neck cancers by harnessing the immune system to recognize and eliminate tumor cells. Immune checkpoint inhibitors, which block inhibitory signals that suppress antitumor immune responses, have demonstrated durable responses and improved survival outcomes in patients with advanced or metastatic head and neck cancers. Recent advancements in immunotherapy include the development of novel checkpoint inhibitors, combination immunotherapy regimens, and predictive biomarkers, as well as the optimization of treatment strategies to overcome resistance mechanisms and enhance response rates.

### ***Supportive Care Measures***

#### ***Oral Mucositis Management***

Oral mucositis is a common side effect of cancer treatment, particularly radiotherapy and chemotherapy, characterized by inflammation and ulceration of the oral mucosa. Recent advancements in oral mucositis management include the use of preventive strategies, such as cryotherapy, low-level laser therapy, and mucosal coating agents, to reduce the severity and duration of mucositis and improve patient comfort and quality of life during treatment. Supportive care measures, such as pain management, nutritional support, and oral hygiene interventions,



are essential components of comprehensive supportive care for patients with head and neck cancers, aimed at minimizing treatment-related morbidity and optimizing treatment outcomes.

### ***Pain Management***

Pain is a common symptom experienced by patients with head and neck cancers, resulting from tumor invasion, nerve compression, mucosal ulceration, and treatment-related side effects. Recent advancements in pain management include the use of multimodal analgesic regimens, including opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), adjuvant medications, and interventional techniques, to achieve optimal pain control and improve patient comfort and quality of life. Palliative care services, such as hospice care and supportive care teams, play a crucial role in addressing the complex physical, psychological, social, and spiritual needs of patients with advanced or incurable head and neck cancers, ensuring compassionate and holistic care throughout the disease trajectory.

#### **Conclusion:**

Advancements in the management of head and neck cancers have transformed the landscape of head and neck oncology, offering patients more personalized, effective, and multidisciplinary treatment options. From early detection and diagnosis to surgical interventions, radiotherapy, chemotherapy, targeted therapies,

immunotherapies, and supportive care measures, the integration of innovative technologies, evidence-based practices, and collaborative approaches has led to improved outcomes and quality of life for individuals affected by head and neck cancers worldwide. Moving forward, continued investment in research, education, and patient-centered care is essential to further enhance our understanding of head and neck cancers, optimize treatment strategies, and improve long-term survival and survivorship outcomes for patients living with this challenging disease.

## **7- ADVANCEMENTS IN THE MANAGEMENT OF GYNECOLOGIC CANCERS**

### ***Background***

Gynecologic cancers encompass a group of malignancies that originate in the female reproductive organs, including the cervix, uterus, ovaries, fallopian tubes, vagina, and vulva. These cancers represent a significant health burden globally and are associated with considerable morbidity and mortality. However, significant advancements have been made in the management of gynecologic cancers over the years, driven by innovations in early detection, surgical techniques, radiotherapy, chemotherapy, targeted therapies, immunotherapies, and supportive care measures. This comprehensive review explores the latest advancements in the management of gynecologic cancers, highlighting key developments in each domain and their impact on patient outcomes and quality of life.

### ***Early Detection and Diagnosis***

#### ***Screening Programs***

Early detection of gynecologic cancers is critical for improving patient outcomes and survival

rates. Screening programs, such as Pap smear tests for cervical cancer and transvaginal ultrasound and CA-125 blood tests for ovarian cancer, aim to identify precancerous lesions or early-stage tumors before they progress to advanced disease. Recent advancements in screening programs include the integration of molecular biomarkers, such as HPV DNA testing for cervical cancer and HE4 and ROMA algorithms for ovarian cancer, which enhance the sensitivity and specificity of screening methods, leading to improved detection rates and reduced false-positive results.

### ***Liquid Biopsy***

Liquid biopsy, which involves the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and other biomarkers in peripheral blood or vaginal fluid, has emerged as a promising diagnostic tool for gynecologic cancers. Liquid biopsy offers several advantages over traditional tissue biopsy, including minimally invasive sampling, real-time monitoring of disease progression, and the detection of molecular alterations associated with treatment response and resistance. Recent studies have demonstrated the utility of liquid biopsy in identifying actionable mutations, monitoring treatment response, and detecting minimal residual disease in patients with gynecologic cancers, highlighting its potential as a noninvasive diagnostic and prognostic tool.

### ***Molecular Imaging***

Molecular imaging techniques, such as PET-CT, MRI, and fluorescence imaging, enable noninvasive visualization and characterization of tumor biology and microenvironment in gynecologic cancers. By targeting specific molecular pathways and biomarkers associated with tumor growth, angiogenesis, and metastasis, molecular imaging provides valuable insights into tumor behavior, treatment response, and prognosis. Recent advancements in molecular imaging technology have led to the development of novel radiotracers and imaging agents, as well as the integration of hybrid imaging modalities, which offer improved sensitivity and specificity for detecting primary tumors, regional lymph node metastases, and distant metastatic sites.

### ***Surgical Interventions***

#### ***Minimally Invasive Surgery***

Minimally invasive surgery, including laparoscopy and robotic-assisted surgery, has revolutionized the surgical management of gynecologic cancers by offering patients less invasive procedures, shorter hospital stays, faster recovery times, and improved cosmetic outcomes compared to traditional open surgery. Recent advancements in minimally invasive surgery technology, including the development of advanced robotic platforms,

novel instrumentation, and enhanced imaging systems, have expanded the indications for minimally invasive surgery to include complex and advanced gynecologic cancers, leading to improved oncologic outcomes and patient satisfaction.

### ***Fertility-Sparing Surgery***

Fertility-sparing surgery is an important consideration for young women diagnosed with early-stage gynecologic cancers who wish to preserve their fertility and reproductive potential. Recent advancements in fertility-sparing surgical techniques, such as ovarian transposition, radical trachelectomy, and ovarian tissue cryopreservation, have enabled more women to undergo conservative surgery without compromising oncologic outcomes or fertility preservation. Patient selection, preoperative counseling, and multidisciplinary collaboration are essential components of fertility-sparing surgery for gynecologic cancers, ensuring optimal outcomes and patient satisfaction.

### ***Sentinel Lymph Node Mapping***

Sentinel lymph node mapping is a minimally invasive surgical technique used to identify and biopsy the first lymph nodes draining the primary tumor site, thereby reducing the need for extensive lymphadenectomy and minimizing the risk of lymphedema and other surgical

complications. Recent advancements in sentinel lymph node mapping techniques, including the use of indocyanine green (ICG) fluorescence imaging, near-infrared (NIR) lymphatic tracers, and molecular imaging agents, have improved the accuracy and reliability of lymph node detection and mapping in gynecologic cancers, leading to more precise staging and tailored treatment strategies.

### ***Radiotherapy***

#### ***Image-Guided Radiation Therapy (IGRT)***

Image-guided radiation therapy (IGRT) is a highly precise radiotherapy technique that uses advanced imaging modalities, such as CT, MRI, and cone-beam CT (CBCT), to visualize the tumor and surrounding organs at risk in real-time during treatment delivery. IGRT allows for the adaptation of radiation fields and doses based on changes in tumor size, shape, and position, thereby minimizing radiation-related toxicity and maximizing tumor control. Recent advancements in IGRT technology, including the integration of online adaptive radiotherapy and motion management techniques, have improved the accuracy and efficacy of radiation delivery for gynecologic cancers, leading to enhanced tumor control rates and reduced treatment-related side effects.

### **Brachytherapy**

Brachytherapy, also known as internal radiation therapy, is a highly effective radiotherapy technique that delivers high doses of radiation directly to the tumor while sparing surrounding normal tissues. Brachytherapy is commonly used for the treatment of cervical cancer, endometrial cancer, and vaginal cancer, either as a primary treatment modality or in combination with external beam radiotherapy. Recent advancements in brachytherapy technology, including the use of image-guided brachytherapy (IGBT), 3D-printed applicators, and intensity-modulated brachytherapy (IMBT), have improved the precision and accuracy of radiation delivery, leading to superior clinical outcomes and reduced treatment-related morbidity in patients with gynecologic cancers.

### **Stereotactic Body Radiotherapy (SBRT)**

Stereotactic body radiotherapy (SBRT) is a highly conformal radiotherapy technique that delivers high doses of radiation to the tumor with extreme precision. SBRT is typically used for the treatment of oligometastatic lesions or recurrent tumors in gynecologic cancers, offering excellent tumor control rates and minimal treatment-related toxicity. Recent advancements in SBRT technology, including the use of advanced

imaging and motion management techniques, have further improved the accuracy and safety of radiation delivery, leading to high rates of local tumor control and prolonged survival in patients with gynecologic cancers.

### **Chemotherapy**

#### **Neoadjuvant Chemotherapy**

Neoadjuvant chemotherapy is an integral component of multimodal treatment approaches for advanced or locally advanced gynecologic cancers, such as ovarian cancer, cervical cancer, and endometrial cancer. Neoadjuvant chemotherapy aims to shrink the tumor, downstage the disease, and improve resectability rates prior to surgery, thereby increasing the likelihood of complete tumor resection and improving long-term survival outcomes. Recent advancements in neoadjuvant chemotherapy regimens, including the use of dose-dense chemotherapy, targeted agents, and combination chemotherapy protocols, have improved response rates and survival outcomes in patients with gynecologic cancers, leading to increased rates of complete cytoreduction and optimal debulking at the time of surgery.

#### **Targeted Therapies**

Targeted therapies, which selectively inhibit specific molecular targets involved in tumor

growth and progression, have revolutionized the treatment of gynecologic cancers by offering more personalized and effective treatment options. Targeted therapies include small molecule inhibitors, monoclonal antibodies, and immune checkpoint inhibitors, which target key signaling pathways such as the PI3K/AKT/mTOR pathway, the angiogenesis pathway, and the DNA damage repair pathway. Recent advancements in targeted therapy include the development of novel agents, combination therapy regimens, and predictive biomarkers to guide patient selection and treatment response, leading to improved clinical outcomes and quality of life for patients with gynecologic cancers.

### ***Immunotherapies***

Immunotherapies, such as immune checkpoint inhibitors and adoptive cell therapies, have emerged as promising treatment modalities for gynecologic cancers by harnessing the power of the immune system to recognize and eliminate tumor cells. Immune checkpoint inhibitors, which block inhibitory signals that suppress antitumor immune responses, have demonstrated durable responses and improved survival outcomes in patients with advanced or metastatic gynecologic cancers. Recent advancements in immunotherapy include the development of novel checkpoint inhibitors, combination immunotherapy regimens, and

predictive biomarkers, as well as the optimization of treatment strategies to overcome resistance mechanisms and enhance response rates, leading to improved long-term survival and quality of life for patients with gynecologic cancers.

### ***Supportive Care Measures***

#### ***Symptom Management***

Symptom management is an essential component of comprehensive cancer care for patients with gynecologic cancers, aimed at alleviating treatment-related side effects and improving quality of life. Common symptoms experienced by patients with gynecologic cancers include pain, fatigue, nausea, vomiting, diarrhea, and sexual dysfunction. Recent advancements in symptom management include the use of multimodal analgesic regimens, antiemetic agents, probiotics, and psychosocial interventions to address the physical, emotional, and psychosocial needs of patients with gynecologic cancers, leading to improved symptom control, treatment adherence, and patient satisfaction.

#### ***Survivorship Care***

Survivorship care is an integral part of cancer care for patients who have completed active treatment for gynecologic cancers, aimed at promoting long-term health and well-being and preventing cancer recurrence and late treatment-

related effects. Survivorship care plans typically include regular follow-up visits, surveillance testing, health screenings, lifestyle interventions, and psychosocial support services tailored to the individual needs of each survivor. Recent advancements in survivorship care include the development of survivorship care guidelines, survivorship care clinics, survivorship care plans, and survivorship-focused research initiatives to optimize long-term outcomes and quality of life for survivors of gynecologic cancers.

### ***Conclusion***

Advancements in the management of gynecologic cancers have transformed the landscape of gynecologic oncology, offering patients more personalized, effective, and multidisciplinary treatment options. From early detection and diagnosis to surgical interventions, radiotherapy, chemotherapy, targeted therapies, immunotherapies, and supportive care measures, the integration of innovative technologies, evidence-based practices, and collaborative approaches has led to improved outcomes and quality of life for individuals affected by gynecologic cancers worldwide. Moving forward, continued investment in research, education, and patient-centered care is essential to further enhance our understanding of gynecologic cancers, optimize treatment strategies, and improve long-term survival and survivorship

outcomes for patients living with these challenging diseases.

## **8- ADVANCEMENTS IN PSYCHO-ONCOLOGY**

### ***Background***

The field of psycho-oncology, positioned at the intersection of psychology and oncology, has emerged as a pivotal discipline in comprehending and tackling the psychological, social, and behavioral aspects of cancer. This multidisciplinary domain centers on understanding the psychological reactions of patients, their families, and caregivers to cancer across all phases, with the aim of alleviating psychological distress and enhancing quality of life. The advent of advancements in psycho-oncology signifies a paradigm shift towards a more holistic approach in cancer care, acknowledging that the fight against cancer encompasses not only the physical aspects but also the mental health challenges accompanying diagnosis, treatment, and survivorship.

Cancer patients endure severe mental and physical symptoms, leading to significant emotional distress. Approximately 30–35% of cancer patients face psychological disorders like anxiety, depression, adjustment difficulties, and neuropsychiatric conditions, including treatment-related cognitive impairments and delirium.



The prevalence varies based on cancer stage and type. Moreover, psychological responses in cancer patients may be influenced by declining performance status, functional limitations, concentration issues, cognitive impairments, and changes in sexual function, among other factors. Patients experiencing both psychosocial and psychiatric symptoms may find it challenging to manage their illness, leading to reduced quality of life, treatment adherence, and outcomes. Numerous scientific cancer associations have developed guidelines for managing psychological distress, emphasizing the importance of identifying and referring patients for timely psychological support. Psycho-oncology offers patient and family care, staff training in psychological support, and collaborative research on various topics, including cancer prevention behaviors, psychiatric management, and coping strategies for cancer patients and their families. This relatively new field has made significant strides in improving the quality of cancer care and is an essential component of the cancer care continuum.

### ***Evolution of Psycho-Oncology***

Psycho-oncology has undergone significant evolution over the past few decades, transitioning from its nascent stages to becoming an integral part of comprehensive cancer care. Its early development was characterized by

a growing recognition of the psychological upheaval experienced by cancer patients and the subsequent need for specialized psychological interventions. Contemporary progress in psycho-oncology has been driven by robust research, technological innovations, and a patient-centered approach to cancer care, resulting in a more nuanced understanding of the psychological dimensions of oncology.

### ***Technological Innovations in Psycho-Oncology***

The incorporation of technology into psycho-oncology has markedly improved the accessibility and efficacy of psychological support for cancer patients and survivors, heralding a transformative change in the field. Innovations like tele-psycho-oncology and mobile health applications have facilitated remote therapeutic sessions and self-management of psychological well-being, overcoming traditional barriers to access. These technologies, along with online support communities, wearable devices, and virtual reality, have expanded the scope of psycho-oncological services, rendering them more personalized and accessible to a broader audience. This has been especially vital in meeting the needs of patients in remote areas or with mobility constraints, ensuring they receive continuous support.

The advancements in psycho-oncology highlight

the pivotal role of technology in enhancing patient care, enabling real-time monitoring and tailored interventions based on individual needs. The utilization of wearable technology to monitor physiological indicators of stress and the application of virtual reality for immersive therapeutic experiences exemplify the innovative approaches being embraced to enhance the psychological well-being of cancer patients. These technological breakthroughs promise a future where comprehensive cancer treatment seamlessly integrates psychological care, thereby enhancing the overall quality of life for those impacted by cancer.

### ***Evidence-Based Interventions***

The progress of psycho-oncology is also evident in the development and validation of evidence-based interventions. Cognitive-behavioral therapies (CBT), mindfulness-based stress reduction (MBSR), and psycho-educational interventions have demonstrated effectiveness in reducing anxiety, depression, and stress among cancer patients. Rooted in empirical evidence, these interventions have become integral to holistic cancer care, providing patients with coping mechanisms to navigate the psychological challenges they encounter.

### ***The Role of Psycho-Oncology in Survivorship***

The concept of survivorship has gained prominence in psycho-oncology, recognizing the long-term psychological effects of cancer extending beyond the acute treatment phase. Advances in psycho-oncology have led to the formulation of survivorship care plans encompassing psychological support, addressing issues such as fear of recurrence, post-traumatic growth, and reintegration into daily life. This holistic approach underscores the significance of ongoing psychological care in enhancing the quality of life and well-being of cancer survivors.

### ***Pediatric Psychosocial Oncology***

Approximately 85% of clinical work in pediatric psychosocial oncology has been published since 1980. Psychotherapy and psychosocial rehabilitation in oncology have been shown to alleviate mental symptoms and overall pain severity. Research indicates that individuals with advanced cancer have significant unmet supportive care needs across various domains, regardless of cancer type. Over time, interventions for cancer-related distress have evolved, including group psychotherapy, cognitive-behavioral therapy, supportive-expressive therapy, cognitive-existential therapy, meaning-centered psychotherapy, and mindfulness programs. Currently, cancer patients' psychological care has advanced significantly, with personalized psychosocial interventions, telehealth, online

support, cognitive-behavioral therapy (CBT), and survivorship planning being key developments.

### ***Telehealth and Online Support***

Telepsychiatry can be implemented in various settings, treatment options, ethnic groups, and age groups, offering new avenues for mental health support to cancer patients, especially amidst health crises like the COVID-19 pandemic. Telemedicine has become a bold and innovative approach in psych-oncology, providing online consultations, emotional support, remote exercise instruction, and cancer detection. Patients prefer telemedicine due to its convenience and accessibility, facilitated by tools like smartphone apps, wearable devices, SMS texting, and internet-delivered interventions. However, the integration of artificial intelligence (AI) in psycho-oncology remains limited, despite its potential to accelerate cancer treatment, prevention, surveillance, and supportive care.

### ***Artificial Intelligence in Cancer Care***

AI algorithms are increasingly utilized for cancer detection and diagnosis, leveraging data from electronic health records (EHRs) and wearable sensors. AI enables assessment of cancer patients' mental well-being, including psychological, cognitive, and emotional states, as well as overall happiness at home, leading to personalized

cancer management recommendations. While AI offers potential benefits, concerns about data security, privacy, and biases in AI models persist. Nonetheless, online support tools, including videoconferencing and Cancer Support Groups (CSGs), offer valuable assistance, support, and empowerment to cancer patients, reducing anxiety and isolation while aiding treatment decisions. Access to reliable information, emotional support, relationship-building, and socialization through online platforms mitigate feelings of loneliness and distress among cancer patients, fostering a sense of camaraderie.

### ***Psychological Impact of Cancer***

Cancer carries significant psychiatric implications, encompassing depression, anxiety, delirium, impaired social relationships, family dysfunction, and potentially suicide risk and adjustment disorders. These psychological challenges profoundly affect a patient's well-being and quality of life. As a sub-specialty, psychiatric oncology addresses various issues, including psychological treatment methods, communication with cancer patients, and the role of life events in cancer maintenance and prognosis. Previously, depression was viewed merely as an emotional response to cancer. However, it's crucial to clinically address the psychological distress experienced by cancer patients and understand the psychological

consequences of the disease.

Despite the considerable psychological challenges faced by cancer patients, this area has not received the necessary attention in terms of clinical and research focus. Many healthcare professionals lack the training to identify psychiatric disorders in cancer patients, leading to a failure to recognize significant sources of morbidity. In the following section, we summarize the most recent information on the psychosocial impacts of cancer.

### **Depression**

Depression spectrum syndromes are often underdiagnosed in the cancer setting, with depressive symptoms linked to worse pain control, social withdrawal, anhedonia, and poorer compliance. Factors contributing to depression symptoms in cancer patients include previous diagnosis of depression, young age, feelings of guilt, worthlessness, substance abuse, poverty, negative experiences with cancer in the family, physical symptoms such as uncontrolled pain, lack of support, and tumor locations. Suicide risk may be present among cancer patients, particularly those who refuse treatment, with requests for euthanasia more common among depressed patients. Self-management strategies can help prevent clinical depression, with support from family and friends often leading to improved well-being within a few weeks.

### **Anxiety**

The diagnosis and treatment of cancer induce high levels of stress, exacerbating preexisting anxiety disorders and potentially interfering with treatment. Factors contributing to anxiety symptoms during cancer treatment include a history of anxiety disorders, functional limitations, and trauma. Specific phobias, such as those related to laboratory tests and clinical examinations, are common in cancer patients and may contribute to adjustment disorders and depression. Anxiety can amplify pain and reduce quality of life, with concerns about disease progression potentially leading to post-traumatic stress disorder (PTSD). Screening for emotional and psychological problems is essential, with treatments focusing on specific diagnoses such as stress management and supportive-expressive therapy. Mind-body approaches can also help alleviate anxiety symptoms.

### **Distress**

Distress and psychological disorders negatively impact cancer patients and their families, ranging from normal distress to formally defined psychiatric problems. Cancer patients often experience subclinical anxiety symptoms and maladaptive coping mechanisms. Factors contributing to distress include physical symptoms, existential concerns, and

psychological symptoms. Patients with cognitive impairment, family conflicts, history of psychiatric disorders, or social problems are more likely to experience distress. Screening for emotional and psychological issues should be part of clinical interventions, with healthcare teams providing emotional support and implementing psychosocial interventions such as cognitive-behavioral coping strategies and group social support.

### ***Adjustment Disorders***

Adjustment disorders stem from identifiable psychosocial stressors and manifest in symptoms like depression, fatigue, generalized anxiety disorder, and impaired occupational functioning, significantly impacting patients' lives. These disorders are frequently reported among cancer patients, with depression, anxiety, mixed disturbance of emotions, and conduct behaviors being the most common types. Various studies have highlighted the benefits of psychosocial interventions, including individual and group counseling, as well as self-management strategies, for cancer patients.

### ***Neurocognitive Disorders***

Neurocognitive disorders often arise as side effects of cancer and its treatment, affecting up to 75% of patients during treatment and 35% post-treatment. Cancer survivors commonly report

issues such as loss of initiative, impaired memory, disorganized behavior or thinking, slower information processing, altered perception, reduced executive function, and difficulty multitasking. Cognitive rehabilitation techniques, including education on cognitive impairments, behavioral training, and cognitive exercises, have shown promise in alleviating these impairments, particularly in patients experiencing cognitive issues post-chemotherapy.

### ***Somatization***

Somatization in cancer patients translates emotional distress or life challenges into physical symptoms, often accompanied by sensations like pain ranging from mild to severe. These symptoms, including excessive thoughts about illness, frequent healthcare visits, and fear of physical activity, can complicate the disease and diminish quality of life. Risk factors for somatization disorder include stressful life events, pain, past trauma, fatigue, anxiety or depression, sexual symptoms, and stress. Cognitive behavioral therapy (CBT) is a beneficial therapy for managing somatization in cancer patients, focusing on cognitive and behavioral elements and incorporating mindfulness and acceptance techniques.

### ***Fear of Cancer Recurrence***

Fear of cancer recurrence (FCR) refers to the

fear of cancer returning or spreading within the body. Factors associated with FCR include impaired quality of life, higher disease stage, poor psychosocial adjustment, physical symptoms like fatigue, depressive symptoms, functional impairments, psychosocial distress, pain, and emotional concerns. While mild levels of FCR can prompt healthy behaviors and self-care, significant distress may require psychological interventions such as cognitive behavioral therapy (CBT) and individual emotion-focused therapy (EFT), as well as participation in cancer support groups. Establishing a supportive network involving family, friends, and healthcare professionals is essential for providing emotional support during this challenging period.

### ***Emotional Support for Cancer Patients***

Emotional support entails interventions such as empathy, acknowledging patients' concerns, and offering reassurance to address the emotional needs of individuals grappling with challenges like cancer. Upon receiving a cancer diagnosis, patients often experience a range of emotions including depression, sadness, fear, helplessness, and anger. Managing emotional distress is crucial for clinicians, as it profoundly impacts patients' well-being. While many cancer patients demonstrate resilience in facing their challenges, it's essential to recognize that they still require support.

Friends and family play a vital role in providing psychosocial and emotional support, aiding patients in utilizing emotion-focused coping mechanisms to regulate their emotions effectively. Unlike anxiety and depression, emotional distress serves as a more accurate indicator of the severity of illness. Healthcare providers can alleviate distress and enhance patients' quality of life by empathetically acknowledging their concerns and offering reassurance, ensuring they feel supported and understood throughout their journey.

### ***Integrative Approaches to Psycho-oncology***

#### ***Mindfulness***

Mindfulness, a practice of nonjudgmental awareness of emotions and experiences moment by moment, is increasingly integrated into cancer care to help patients navigate the disease's challenges. It mitigates anxiety, self-harm, and aggressive behaviors, fostering motivation to overcome mental health issues and illness. Mindfulness meditation practices, including body scans, mindful breathing, and Hatha yoga poses, effectively manage treatment side effects and disease symptoms, proving cost-effective compared to traditional treatments. These practices have demonstrated positive outcomes in trials and are progressively incorporated into cancer care protocols.

### ***Meditation and Yoga***

Meditation offers stress reduction and relaxation benefits, crucial for individuals at various stages of their cancer journey. Mindfulness-based stress reduction (MBSR) enhances psychological well-being, benefiting both patients and their partners. Similarly, yoga and meditation alleviate stress, anxiety, and pain, improve sleep quality, boost energy levels, and strengthen the immune system. However, patients with specific medical conditions should practice caution, such as those with pleural effusion or abdominal surgeries. Mindfulness exercises like sitting meditation, body scan, and mindful movement promote self-assurance and positivity in coping with cancer-related challenges.

### ***Relaxation Techniques***

Progressive muscle relaxation (PMR) and guided imagery (GI) alleviate stress, anxiety, and depression while enhancing mood and quality of life. These techniques effectively manage chemotherapy-related side effects such as nausea, vomiting, pain, and fatigue. Benson's relaxation method (BRM), which combines meditation with conviction, is widely utilized by family caregivers and cancer patients. BRM involves muscle relaxation, slow breathing, and focused attention on body sensations, fostering a sense of calmness and well-being. Learning these techniques

strengthens the nurse-patient relationship and requires no specialized equipment.

### ***Conclusion***

The advancements in psycho-oncology signify a significant shift towards acknowledging and addressing the psychological dimensions of cancer care. By integrating technological innovations, evidence-based interventions, and a focus on survivorship, psycho-oncology continues to evolve, bolstering its ability to support survivors, families, and caregivers through the cancer journey. As this field progresses, it holds the promise of further enhancing psychological well-being and quality of life for those affected by cancer, ushering in a new era in the comprehensive care of oncology patients. Recent studies, such as the systematic review by Amani et al. (2024) on chemotherapy-induced cognitive impairment, underscore the importance of addressing cognitive challenges in breast cancer survivors, further enriching our understanding of the critical role of psycho-oncology.

## **9- ADVANCEMENTS IN THE MANAGEMENT OF OTHER CANCERS**

### ***Advancements in the Management of Brain Tumors***

Recent advancements in the management of brain tumors have been shaped by the World Health Organization's (WHO) classification system, which categorizes these tumors based on histologic features and presumed cellular origin. The 2007 update to the Central Nervous System (CNS) classification system introduced a grading scheme linking histologic diagnosis directly to tumor grade. The WHO system identifies seven major categories of CNS tumors, containing various tissues and origins. Despite the relatively low incidence of primary brain tumors compared to other cancers, their impact on morbidity and mortality is substantial. With approximately 69,720 new cases expected in the United States annually, primary CNS tumors, particularly malignant gliomas, contribute significantly to patient impairment and a combined mortality rate of around 60%. The essay will delve into recent breakthroughs that address the challenges posed by these aggressive tumors, ranging from diagnostic improvements to novel therapeutic



approaches, aiming to enhance patient outcomes and quality of life.

Over the past few decades, the diagnosis of both primary and metastatic brain tumors has shown a notable increase, with rates of 6.6 per 100,000 person-years for primary tumors and 8.3 to 11 per 100,000 person-years for metastatic ones. This surge in diagnoses is attributed to improved diagnostic modalities and increased access to neurosurgical services. Technological advances have significantly impacted the outcomes for brain tumor patients, particularly in the realm of neurosurgery. With evolving paradigms in low-grade glioma (LGG) management, the traditional "wait-and-see" approach is shifting towards favoring early surgical intervention. Conversely, for high-grade gliomas (HGG), early surgical intervention is emphasized for pathologic diagnosis and maximal safe tumor debulking. Innovations such as functional MRI (fMRI), diffusion tensor imaging (DTI), intraoperative MRI (iMRI), 5-aminolevulinic acid (5-ALA)-guided resection, and laser interstitial thermal therapy (LITT) are highlighted as promising tools that contribute to more precise preoperative planning and safer surgical resection of intracranial neoplasms.

In the ever-evolving landscape of brain tumor management, recent advancements in surgical approaches showcase a transformative era in neurosurgery. Minimally invasive techniques,

such as keyhole craniotomies and tubular retractors, have emerged as pivotal tools, offering reduced soft tissue and bone trauma, decreased postoperative complications, and improved cosmetic results. Keyhole approaches, supported by studies like Tobler and Stanley's stereotactic-guided keyhole craniotomies, demonstrate their efficacy in achieving gross total resection of brain metastases with minimal morbidity. Additionally, the supraorbital (SO) "eyebrow" craniotomy, a keyhole modification, emerges as a valuable alternative for lesions in the orbitofrontal surface and frontal pole. Tubular retractors, like the ViewSite Brain Access System (VBAS) and BrainPath system, enhance visualization and access, facilitating high-efficacy, low-morbidity resection of deep-seated metastases.

Supramarginal resection techniques, aiming for microscopic total resection, present a promising avenue to address challenges posed by infiltrating metastatic cells beyond the glial pseudocapsule. Studies by Yoo et al. and Kamp et al. reveal the potential benefits of supramarginal resection in improving local control and progression of metastatic disease, contributing to enhanced survival rates. The strategic use of brachytherapy, particularly cesium-131 (131Cs), adds a dynamic dimension to adjuvant therapies for brain metastases. With lower rates of radiation necrosis and excellent local control, 131Cs brachytherapy emerges as a promising modality. Ongoing

randomized controlled trials, such as the one comparing post-surgical <sup>131</sup>Cs brachytherapy vs. stereotactic radiosurgery (SRS), are poised to offer critical insights into the optimal use-cases of brachytherapy in the treatment paradigm. These collective advancements reflect a comprehensive and patient-centered approach, illustrating the dynamic nature of neurosurgical management and laying the foundation for improved outcomes in the realm of brain tumor treatment.

Cancer remains the world's most devastating disease, leading to significant mortality rates. Despite early detection and treatment efforts, conventional methods prove inefficient, while the selectivity and toxicity issues of traditional chemotherapy pose substantial challenges. Hence, there's a pressing need for safe and effective cancer diagnosis and treatment options.

Brain cancer incidence rates are escalating globally for both sexes, underscoring the importance of prevention and research initiatives. Due to ineffective diagnosis and profiling, brain tumors persist as one of the most aggressive cancer types. Brain tumors, generally, denote uncontrolled growths of brain tissue. In 1863, Virchow published the first report on brain tumor classification. The 2016 WHO Classification of Central Nervous System Tumors defines tumor entities based on molecular parameters and histology. This classification introduced new

entities like IDH-wildtype, H3 K27M-mutant, and RELA fusion-positive ependymoma, significantly restructuring gliomas, medulloblastomas, and embryonal tumors.

Glioma presents a formidable challenge due to delayed diagnosis. Liquid biopsy techniques, including next-generation sequencing (NGS), droplet digital PCR (ddPCR), and quantitative polymerase chain reactions (qPCR), represent recent advances in clinical diagnosis. Despite challenges like high capital costs and turnaround delays, NGS, especially Nanopore sequencing technology, offers promising diagnostic potential.

The 2021 WHO Classification of CNS Tumors recommends evaluating CDKN2A/B deletion and 1p/19q codeletion for characterizing IDH-mutant gliomas. Nanopore sequencing facilitates the simultaneous identification of these deletions, along with other epigenomic changes crucial for cancer entity identification.

Glioblastoma (GBM), a typical brain tumor, is typically managed with surgical resection, radiotherapy, and chemotherapy, yet its incidence is rising, quality of life changes, and prognosis remains poor. NGS is increasingly utilized to detect targetable mutations in GBM, offering potential breakthroughs in treatment options for recurrent cases.

Nanotechnology holds promise in in-vivo imaging

and cancer cell detection, offering a quick, safe, cost-effective, and efficient approach to cancer management. Nanomaterials, with their ability to traverse cell and tissue barriers like the blood-brain barrier, could enhance drug delivery and prolong drug circulation within the brain, thus advancing glioblastoma treatment. However, before clinical translation, potential side effects and toxicity issues require careful consideration.

### ***Advancements in the Management of Osteosarcoma***

#### ***Background***

Osteosarcoma stands as the most common primary malignant bone tumor, significantly affecting adolescents and young adults during periods of rapid bone growth. Originating from mesenchymal tissues, it is characterized by malignant osteoid-producing cells. Incidence peaks occur between 15-19 years of age and later in the 7th-8th decade, with primary sites most commonly found around the knee or in the proximal femur and tibia. The current standard of care combines surgery with neoadjuvant and adjuvant chemotherapy, resulting in long-term survival in approximately 60% of patients with localized disease. However, metastases develop in up to 30% of cases, primarily to the lungs, leading to a poorer prognosis. Histologic response to preoperative chemotherapy serves

as a crucial prognostic indicator, with over 90% tumor necrosis correlating with improved outcomes. Despite significant advancements in multidisciplinary treatment, about one-third of patients still experience local recurrence or metastatic disease. For those with recurrent or metastatic osteosarcoma at diagnosis, the five-year survival rate is only 20-30%. This underscores the imperative for novel therapeutic strategies guided by a deeper understanding of osteosarcoma's complex biology, genetics, and molecular underpinnings. Precision oncology approaches targeting specific pathways hold promise to enhance outcomes for this challenging disease.

#### ***Diagnosis and Staging***

Given the intricate nature of primary bone malignancies, a multidisciplinary approach is pivotal for accurate osteosarcoma diagnosis. Patients may initially present with non-specific musculoskeletal complaints such as localized pain triggered by weight-bearing activities or recent trauma. In some cases, intermittent discomfort leads to an abnormal gait resembling a limp. Various serum markers can aid in diagnosis and treatment monitoring. Alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) levels offer valuable insights, with ALP exhibiting the strongest correlation to osteosarcoma. Elevated ALP is associated with larger tumor volumes and a

poorer prognosis.

Plain radiographs of the affected bone serve as the initial investigation for suspected osteosarcoma, revealing any abnormalities warranting further imaging. Magnetic resonance imaging (MRI) and computed tomography (CT) elucidate soft tissue involvement and assess for lung metastases, respectively. Bone scintigraphy effectively identifies metastases, serving as a potent prognostic indicator. Experimental modalities like positron emission tomography (PET) may potentially supplement bone scintigraphy in the future. Combined PET/CT correlates with progression-free survival, overall survival, and histologic response in osteosarcoma. Studies suggest PET/CT surpasses bone scintigraphy for detecting metastases and can noninvasively determine osteonecrotic extent as an alternative to biopsy-requiring grading. Tissue biopsy provides the definitive diagnosis and histologic subtype critical for informing chemotherapy. Osteosarcoma is staged using the Musculoskeletal Tumor Society or American Joint Commission on Cancer TNM classification. The TNM system considers tumor size/invasion, nodal/metastatic spread, and grade to guide prognosis and care. Through the multidisciplinary integration of advanced diagnostics, personalized identification, and characterization of osteosarcoma, optimized treatment planning matched to individual tumor

profiles is now supported. Continued refinement of biomarkers and imaging holds promise to further advance precision management of this disease.

### ***Advancements in Biologic Therapies for Musculoskeletal Cancers***

#### ***Background***

Bone cancer, while relatively rare compared to other cancers, poses significant challenges in diagnosis and treatment. Conventional therapies like surgery, chemotherapy, and radiation have limitations in effectiveness and often result in severe side effects. However, recent advances in biologic therapies offer promising alternatives for treating various types of Musculoskeletal Cancers. In this review, we delve into Biologic Therapies for bone, soft tissue, and cartilage cancers.

#### ***Osteosarcoma***

Osteosarcoma stands as the most prevalent primary malignant bone tumor, predominantly affecting children and adolescents. Biologic therapies for osteosarcoma aim to target tumor cells while minimizing harm to healthy tissue. Exosomes, tiny extracellular vesicles released by cells, have emerged as potential carriers for delivering therapeutic cargo to tumor

sites. Studies indicate that exosomes loaded with anticancer drugs or tumor-suppressing microRNAs effectively inhibit osteosarcoma growth and metastasis. Additionally, nanoparticle-based drug delivery systems show promise in enhancing chemotherapy efficacy while reducing systemic toxicity. Stem cell therapy, especially mesenchymal stem cells (MSCs), holds potential for promoting tissue regeneration and inhibiting tumor progression in osteosarcoma.

### **Chondrosarcoma**

Chondrosarcoma ranks as the second most common primary malignant bone tumor, characterized by tumor cells producing cartilage matrix. Conventional treatments for chondrosarcoma often fall short due to its resistance to chemotherapy and radiation. Biologic therapies targeting the unique characteristics of chondrosarcoma offer novel treatment avenues. Exosome-based therapy shows promise in delivering therapeutic cargo, such as tumor-suppressing microRNAs or anti-angiogenic agents, to chondrosarcoma cells. MicroRNA-based therapeutics, regulating gene expression, have demonstrated the ability to inhibit chondrosarcoma growth and metastasis in preclinical models. Nanoparticle-mediated delivery of small interfering RNAs (siRNAs)

targeting specific oncogenes holds potential for overcoming drug resistance in chondrosarcoma. Moreover, stem cell-based approaches, including MSC therapy and chondrocyte transplantation, aim to restore cartilage integrity and inhibit tumor growth in chondrosarcoma.

### **Ewing Sarcoma**

Ewing sarcoma represents a rare yet aggressive bone cancer primarily affecting children and young adults. Current treatment options, including chemotherapy, surgery, and radiation therapy, often result in long-term side effects. Biologic therapies targeting the molecular pathways involved in Ewing sarcoma present new opportunities for improving patient outcomes. Exosome-based delivery of tumor-suppressing microRNAs or small molecule inhibitors has shown efficacy in inhibiting Ewing sarcoma cell proliferation and metastasis. MicroRNA-based therapeutics targeting oncogenic fusion proteins, such as EWS-FLI1, hold promise for disrupting tumor growth in Ewing sarcoma. Nanoparticle-mediated delivery of siRNAs or gene editing tools, like CRISPR-Cas9, offer innovative approaches for targeting specific genetic alterations driving Ewing sarcoma. Additionally, stem cell-based immunotherapies, like chimeric antigen receptor (CAR) T-cell therapy, aim to harness the immune system to recognize and eliminate Ewing sarcoma

cells.

### ***Liposarcoma***

Liposarcoma, a malignant tumor originating from adipose tissue, constitutes a significant portion of soft tissue sarcomas. Treatment options for liposarcoma are often limited, especially for advanced or metastatic cases. Biologic therapies targeting crucial pathways involved in liposarcoma's development provide new treatment avenues. Exosome-based delivery of tumor-suppressing microRNAs or anti-angiogenic agents has demonstrated effectiveness in inhibiting liposarcoma growth and metastasis. MicroRNA-based therapeutics targeting oncogenic signaling pathways, such as the PI3K-Akt-mTOR pathway, hold promise for overcoming drug resistance in liposarcoma. Nanoparticle-mediated delivery of siRNAs targeting specific oncogenes or immune checkpoint inhibitors offers innovative approaches to enhancing immunotherapy efficacy in liposarcoma. Additionally, stem cell-based immunotherapies, like dendritic cell vaccines, aim to activate the immune system to recognize and eliminate liposarcoma cells.

### ***Synovial Sarcoma***

Synovial sarcoma, a rare yet aggressive soft tissue tumor typically found near large joints, poses significant treatment challenges. Current

treatment options include surgery, chemotherapy, and radiation therapy, but outcomes remain poor for advanced or metastatic disease. Biologic therapies targeting molecular pathways involved in synovial sarcoma pathogenesis offer new avenues for treatment. Exosome-based delivery of tumor-suppressing microRNAs or small molecule inhibitors has shown efficacy in inhibiting synovial sarcoma cell proliferation and metastasis. MicroRNA-based therapeutics targeting oncogenic fusion proteins, such as SYT-SSX, hold promise for disrupting tumor growth in synovial sarcoma. Nanoparticle-mediated delivery of siRNAs targeting specific genetic alterations driving synovial sarcoma offers innovative approaches to personalized treatment. Additionally, stem cell-based immunotherapies, such as tumor-infiltrating lymphocyte therapy, aim to harness the immune system to recognize and eliminate synovial sarcoma cells.

### ***Rhabdomyosarcoma (RMS)***

RMS, the most common soft tissue sarcoma in children and adolescents, is characterized by primitive mesenchymal cells with skeletal muscle differentiation. Biologic interventions targeting RMS include exosome-based therapy, where exosomes derived from mesenchymal stem cells (MSCs) exhibit tumor-suppressive effects by delivering cargo molecules that inhibit RMS

cell proliferation and metastasis. Additionally, microRNA-based therapeutics can modulate key signaling pathways involved in RMS growth and invasion. Nanoparticle-based drug delivery systems offer precise and targeted delivery of anti-cancer agents to RMS tumors while minimizing off-target effects. Stem cell therapy holds promise for RMS treatment through regenerative and immunomodulatory properties.

### ***Leiomyosarcoma (LMS)***

LMS arises from smooth muscle cells and presents challenges in treatment due to its aggressive nature and limited response to conventional therapies. Biologic advancements offer new avenues for LMS therapy, including exosome-mediated communication, microRNA dysregulation, nanoparticle-based drug delivery, and stem cell therapy. Exosomes derived from MSCs can modulate the tumor microenvironment and sensitize LMS cells to chemotherapy. MicroRNAs play a crucial role in LMS pathogenesis and can be targeted to inhibit tumor growth and metastasis. Nanoparticle-based drug delivery systems enable targeted delivery of therapeutic agents to LMS tumors, enhancing treatment efficacy while minimizing systemic toxicity. Stem cell therapy offers potential for immunomodulation and tissue regeneration in LMS.

### ***Giant Cell Tumor (GCT)***

GCT, a benign but locally aggressive bone tumor characterized by multinucleated giant cells, presents biologic approaches focusing on targeting the tumor microenvironment and modulating osteoclast activity. Exosomes derived from MSCs have been explored for their potential in inhibiting GCT growth and promoting bone regeneration. MicroRNA-based therapies can regulate osteoclastogenesis and tumor cell proliferation in GCT. Nanoparticle-based drug delivery systems offer targeted delivery of anti-resorptive agents to GCT lesions, reducing bone destruction and tumor recurrence. Stem cell therapy holds promise for promoting bone healing and preventing GCT recurrence through tissue regeneration and immunomodulation.





## REFERENCES

1. Allano G, George B, Minello C, Burnod A, Maindet C, Lemaire A. Strategies for interventional therapies in cancer-related pain-a crossroad in cancer pain management. *Support Care Cancer*. 2019;27(8):3133-45.
2. Alobuia W, Gillis A, Kebebew E. Contemporary Management of Anaplastic Thyroid Cancer. *Curr Treat Options Oncol*. 2020;21(10):78.
3. Amiel CR, Fisher HM, Carver CS, Antoni MH. The importance of stress management among postresection breast cancer patients. *Future Oncol*. 2016;12(24):2771-4.
4. Anderson LJ, Albrecht ED, Garcia JM. Update on Management of Cancer-Related Cachexia. *Curr Oncol Rep*. 2017;19(1):3.
5. Araque KA, Gubbi S, Klubo-Gwiedzinska J. Updates on the Management of Thyroid Cancer. *Horm Metab Res*. 2020;52(8):562-77.
6. Arring NM, Barton DL, Brooks T, Zick SM. Integrative Therapies for Cancer-Related Fatigue. *Cancer J*. 2019;25(5):349-56.
7. Ascenzi F, De Vitis C, Maugeri-Saccà M, Napoli C, Ciliberto G, Mancini R. SCD1, autophagy and cancer: implications for therapy. *J Exp Clin Cancer Res*. 2021;40(1):265.
8. Ashai N, Prasad P, Rajdev L. Multimodality Management of Localized Biliary Cancer. *Curr*

*Treat Options Oncol*. 2019;20(7):58.

9. Bail JR, Traeger L, Pirl WF, Bakitas MA. Psychological Symptoms in Advanced Cancer. *Semin Oncol Nurs*. 2018;34(3):241-51.
10. Banasiak W, Zymliński R, Undas A. Optimal management of cancer patients with acute coronary syndrome. *Pol Arch Intern Med*. 2018;128(4):244-53.
11. Basu S, Dong Y, Kumar R, Jeter C, Tang DG. Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis. *Semin Cancer Biol*. 2022;78:90-103.
12. Beharee N, Shi Z, Wu D, Wang J. Diagnosis and treatment of cervical cancer in pregnant women. *Cancer Med*. 2019;8(12):5425-30.
13. Bennett MI, Eisenberg E, Ahmedzai SH, Bhaskar A, O'Brien T, Mercadante S, et al. Standards for the management of cancer-related pain across Europe-A position paper from the EFIC Task Force on Cancer Pain. *Eur J Pain*. 2019;23(4):660-8.
14. Bhatt A, Kamath S, Murthy SC, Raja S. Multidisciplinary Evaluation and Management of Early Stage Esophageal Cancer. *Surg Oncol Clin N Am*. 2020;29(4):613-30.
15. Biondo S, Fracalvieri D, Golda T, Frago R, Trenti L, Kreisler E. Update on advances and controversy in rectal cancer treatment. *Tech Coloproctol*. 2016;20(3):145-52.
16. Blum MA, Takashi T, Suzuki A, Ajani JA. Management of localized gastric cancer. *J Surg Oncol*. 2013;107(3):265-70.

17. Bolger JC, Donohoe CL, Lowery M, Reynolds JV. Advances in the curative management of oesophageal cancer. *Br J Cancer*. 2022;126(5):706-17.
18. Bossaer JB, Geraci SA, Chakraborty K. Cardiovascular Toxicity and Management of Targeted Cancer Therapy. *Am J Med Sci*. 2016;351(5):535-43.
19. Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and Management of Endometrial Cancer. *Am Fam Physician*. 2016;93(6):468-74.
20. Brozović G, Lesar N, Janev D, Bošnjak T, Muhaxhiri B. CANCER PAIN AND THERAPY. *Acta Clin Croat*. 2022;61(Suppl 2):103-8.
21. Campen CJ, Dragovich T, Baker AF. Management strategies in pancreatic cancer. *Am J Health Syst Pharm*. 2011;68(7):573-84.
22. Carlson GW. The Management of Breast Cancer Detected by Reduction Mammoplasty. *Clin Plast Surg*. 2016;43(2):341-7.
23. Carmona-Bayonas A, Sánchez-Cánovas M, Plasencia JM, Custodio A, Martínez de Castro E, Virizuela JA, et al. Key points to optimizing management and research on cancer-associated thrombosis. *Clin Transl Oncol*. 2018;20(2):119-26.
24. Cersosimo RJ. Management of advanced colorectal cancer, Part 1. *Am J Health Syst Pharm*. 2013;70(5):395-406.
25. Chahoud J, Kohli M, Spiess PE. Management of Advanced Penile Cancer. *Mayo Clin Proc*. 2021;96(3):720-32.

26. Chakraborty M, Pandey M. Caring for cancer patients in the Covid pandemic: choosing between the devil and deep sea. *World J Surg Oncol*. 2020;18(1):220.
27. Colvin H, Yamamoto K, Wada N, Mori M. Hereditary Gastric Cancer Syndromes. *Surg Oncol Clin N Am*. 2015;24(4):765-77.
28. Corthay A, Bakacs T, Thangavelu G, Anderson CC. Tackling cancer cell dormancy: Insights from immune models, and transplantation. *Semin Cancer Biol*. 2022;78:5-16.
29. Creutzberg CL, Lu KH, Fleming GF. Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease. *J Clin Oncol*. 2019;37(27):2490-500.
30. Crombez P, Bron D, Michiels S. Multicultural approaches of cancer pain. *Curr Opin Oncol*. 2019;31(4):268-74.
31. Dahan A, Hellinga MD, Niesters M, Fleisch J. [Pain in cancer]. *Ned Tijdschr Geneesk*. 2023;167.
32. Dalal S, Bruera E. Pain Management for Patients With Advanced Cancer in the Opioid Epidemic Era. *Am Soc Clin Oncol Educ Book*. 2019;39:24-35.
33. Dasari S, Kathera C, Janardhan A, Praveen Kumar A, Viswanath B. Surfacing role of probiotics in cancer prophylaxis and therapy: A systematic review. *Clin Nutr*. 2017;36(6):1465-72.
34. Davis MP, Khoshknabi D, Yue GH. Management of fatigue in cancer patients. *Curr Pain Headache Rep*. 2006;10(4):260-9.

35. De Felice F, de Vincentiis M, Valentini V, Musio D, Mezi S, Lo Mele L, et al. Follow-up program in head and neck cancer. *Crit Rev Oncol Hematol*. 2017;113:151-5.
36. Denbo JW, Fleming JB. Definition and Management of Borderline Resectable Pancreatic Cancer. *Surg Clin North Am*. 2016;96(6):1337-50.
37. Deng G. Integrative Medicine Therapies for Pain Management in Cancer Patients. *Cancer J*. 2019;25(5):343-8.
38. Desai NV, Sliesoraitis S, Hughes SJ, Trevino JG, Zlotecki RA, Ivey AM, et al. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. *Cancer Med*. 2015;4(8):1224-39.
39. Desandes E, Lacour B, Clavel J. [Cancer in adolescents and young adults in France: Epidemiology and pathways of care]. *Bull Cancer*. 2016;103(12):957-65.
40. Dios PD, Lestón JS. Oral cancer pain. *Oral Oncol*. 2010;46(6):448-51.
41. Duggan C, Dvaladze AL, Tsu V, Jeronimo J, Constant TKH, Romanoff A, et al. Resource-stratified implementation of a community-based breast cancer management programme in Peru. *Lancet Oncol*. 2017;18(10):e607-e17.
42. Elsamany S, Abdullah S. Triple-negative breast cancer: future prospects in diagnosis and management. *Med Oncol*. 2014;31(2):834.
43. Epstein JB, Miaskowski C. Oral Pain in the Cancer Patient. *J Natl Cancer Inst Monogr*. 2019;2019.(53)
44. Ernani V, Saba NF. Oral Cavity Cancer: Risk Factors, Pathology, and Management. *Oncology*. 2015;89(4):187-95.
45. Fakhrejehani F, Madan RA, Dahut WL. Management Options for Biochemically Recurrent Prostate Cancer. *Curr Treat Options Oncol*. 2017;18(5):26.
46. Ferrell BR. Family Caregiving and Cancer Pain Management. *Anesth Analg*. 2019;129(5):1408-13.
47. Filella X, Foj L, Milà M, Augé JM, Molina R, Jiménez W. PCA3 in the detection and management of early prostate cancer. *Tumour Biol*. 2013;34(3):1337-47.
48. Filippiadis DK, Tselikas L, Bazzocchi A, Efthymiou E, Kelekis A, Yevich S. Percutaneous Management of Cancer Pain. *Curr Oncol Rep*. 2020;22(5):43.
49. Finet JE. Management of Heart Failure in Cancer Patients and Cancer Survivors. *Heart Fail Clin*. 2017;13(2):253-88.
50. Fish D, Temple LK. Functional consequences of colorectal cancer management. *Surg Oncol Clin N Am*. 2014;23(1):127-49.
51. Fisher CS, Margenthaler JA, Hunt KK, Schwartz T. The Landmark Series: Axillary Management in Breast Cancer. *Ann Surg Oncol*. 2020;27(3):724-9.
52. Fishman JA, Hogan JI, Maus MV. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies. *Clin*

Infect Dis. 2019;69(6):909-20.

53. Fuller C, Huang H, Thienprayoon R. Managing Pain and Discomfort in Children with Cancer. *Curr Oncol Rep.* 2022;24(8):961-73.

54. Furrukh M, Qureshi A. Treatment Of Breast Cancer; Review And Updates. *J Ayub Med Coll Abbottabad.* 2018;30(2):264-74.

55. Gajra A, Akbar SA, Din NU. Management of Lung Cancer in the Elderly. *Clin Geriatr Med.* 2016;32(1):81-95.

56. Galloway TJ, Ridge JA. Treatment of Head and Neck Cancer-Sometimes, Less Is More. *JAMA Otolaryngol Head Neck Surg.* 2019;145(12):1167-9.

57. Garg PK, Pandey D, Sharma J. The surgical management of gallbladder cancer. *Expert Rev Gastroenterol Hepatol.* 2015;9(2):155-66.

58. Gershenson DM, Okamoto A, Ray-Coquard I. Management of Rare Ovarian Cancer Histologies. *J Clin Oncol.* 2019;37(27):2406-15.

59. Giridhar KV, Kohli M. Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer. *Mayo Clin Proc.* 2017;92(10):1564-82.

60. Goebel J, Valinski S, Hershey DS. Improving Coordination of Care Among Healthcare Professionals and Patients With Diabetes and Cancer. *Clin J Oncol Nurs.* 2016;20(6):645-51.

61. Goodlev ER, Discala S, Darnall BD, Hanson M, Petok A, Silverman M. Managing Cancer

Pain, Monitoring for Cancer Recurrence, and Mitigating Risk of Opioid Use Disorders: A Team-Based, Interdisciplinary Approach to Cancer Survivorship. *J Palliat Med.* 2019;22(11):1308-17.

62. Gosain R, Miller K. Symptoms and symptom management in long-term cancer survivors. *Cancer J.* 2013;19(5):405-9.

63. Goto H, Kiyohara Y, Shindo M, Yamamoto O. Symptoms of and Palliative Treatment for Unresectable Skin Cancer. *Curr Treat Options Oncol.* 2019;20(4):34.

64. Greco MT, Roberto A, Corli O, Deandrea S, Bandieri E, Cavuto S, et al. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. *J Clin Oncol.* 2014;32(36):4149-54.

65. Greenlee H, Santiago-Torres M, McMillen KK, Ueland K, Haase AM. Helping Patients Eat Better During and Beyond Cancer Treatment: Continued Nutrition Management Throughout Care to Address Diet, Malnutrition, and Obesity in Cancer. *Cancer J.* 2019;25(5):320-8.

66. Grulich AE, Jin F, Poynten IM, Vajdic CM. HIV, cancer, and aging. *Sex Health.* 2011;8(4):521-5.

67. Gungorduk K, Sahbaz A, Ozdemir A, Gokcu M, Sancı M, Köse MF. Management of cervical cancer during pregnancy. *J Obstet Gynaecol.* 2016;36(3):366-71.

68. Gurel C, Inetas G, Hortu I, Tunc E, Kuscu GC, Dindaroglu FC, et al. Cancer and Cancer Stem

Cells: New Molecular Perspectives. *Crit Rev Oncog.* 2019;24(1):99-104.

69. Habr-Gama A, São Julião GP, Perez RO. Nonoperative management of rectal cancer: identifying the ideal patients. *Hematol Oncol Clin North Am.* 2015;29(1):135-51.

70. Hagen NA, Biondo P, Stiles C. Assessment and management of breakthrough pain in cancer patients: current approaches and emerging research. *Curr Pain Headache Rep.* 2008;12(4):241-8.

71. Hanker AB, Sudhan DR, Arteaga CL. Overcoming Endocrine Resistance in Breast Cancer. *Cancer Cell.* 2020;37(4):496-513.

72. Heigl P. [Cancer pain management]. *Orv Hetil.* 2014;155(3):93-9.

73. Henry-Tillman RS. The tale of two stories: Challenges and innovations in breast cancer management. *Am J Surg.* 2018;215(6):1062-5.

74. Hill BL, Lefkowitz C. Strategies for Optimizing Perioperative Pain Management for the Cancer Patient. *Surg Oncol Clin N Am.* 2021;30(3):519-34.

75. Hubbard JM. Management of Colorectal Cancer in Older Adults. *Clin Geriatr Med.* 2016;32(1):97-111.

76. Hui D, Bruera E. Models of Palliative Care Delivery for Patients With Cancer. *J Clin Oncol.* 2020;38(9):852-65.

77. Iaccarino I, Klapper W. LncRNA as Cancer Biomarkers. *Methods Mol Biol.* 2021;2348:27-41.

78. Igarashi Y, Sasada T. Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy. *J Immunol Res.* 2020;2020:5825401.

79. Igawa-Silva W, Wu S, Harrigan R. Music and cancer pain management. *Hawaii Med J.* 2007;66(11):292-5.

80. Imazio M, Colopi M, De Ferrari GM. Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes. *Heart.* 2020;106(8):569-74.

81. Ing JW. Head and Neck Cancer Pain. *Otolaryngol Clin North Am.* 2017;50(4):793-806.

82. Irfan M, Delgado RZR, Frias-Lopez J. The Oral Microbiome and Cancer. *Front Immunol.* 2020;11:591088.

83. Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Pappas S, Gamblin TC, et al. Management of acute cholecystitis in cancer patients: a comparative effectiveness approach. *Surg Endosc.* 2014;28(5):1505-14.

84. Joharatnam-Hogan N, Chambers P, Dhatariya K, Board R. A guideline for the outpatient management of glycaemic control in people with cancer. *Diabet Med.* 2022;39(1):e14636.

85. Johnson CA, James D, Marzan A, Armaos M. Cervical Cancer: An Overview of Pathophysiology and Management. *Semin Oncol Nurs.* 2019;35(2):166-74.

86. Kahan B. Cancer pain and current theory

for pain control. *Phys Med Rehabil Clin N Am.* 2014;25(2):439-56.

87. Karuturi M, VanderWalde N, Muss H. Approach and Management of Breast Cancer in the Elderly. *Clin Geriatr Med.* 2016;32(1):133-53.

88. Kasuga A, Okamoto T, Udagawa S, Mori C, Mie T, Furukawa T, et al. Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. *Int J Mol Sci.* 2022;23.(3)

89. Kauppila JH, Lagergren J. The surgical management of esophago-gastric junctional cancer. *Surg Oncol.* 2016;25(4):394-400.

90. Kelly RJ. Emerging Multimodality Approaches to Treat Localized Esophageal Cancer. *J Natl Compr Canc Netw.* 2019;17(8):1009-14.

91. Khokhar M, Milas M. Management of Nodal Disease in Thyroid Cancer. *Surg Clin North Am.* 2019;99(4):611-32.

92. Kilari D, Mohile SG. Management of cancer in the older adult. *Clin Geriatr Med.* 2012;28(1):33-49.

93. Knabben L, Mueller MD. Breast cancer and pregnancy. *Horm Mol Biol Clin Investig.* 2017;32.(1)

94. Koulouris AI, Banim P, Hart AR. Pain in Patients with Pancreatic Cancer: Prevalence, Mechanisms, Management and Future Developments. *Dig Dis Sci.* 2017;62(4):861-70.

95. Kuiken NS, Rings EH, Tissing WJ. Risk analysis, diagnosis and management

of gastrointestinal mucositis in pediatric cancer patients. *Crit Rev Oncol Hematol.* 2015;94(1):87-97.

96. Kurtin S, Fuoto A. Pain Management in the Cancer Survivor. *Semin Oncol Nurs.* 2019;35(3):284-90.

97. Kwon JH. Overcoming barriers in cancer pain management. *J Clin Oncol.* 2014;32(16):1727-33.

98. Lau J, Flamer D, Murphy-Kane P. Interventional anesthesia and palliative care collaboration to manage cancer pain: a narrative review. *Can J Anaesth.* 2020;67(2):235-46.

99. Le TA, Jivalagian A, Hiba T, Franz J, Ahmadzadeh S, Eubanks T, et al. Multi-agent Systems and Cancer Pain Management. *Curr Pain Headache Rep.* 2023;27(9):379-86.

100. Lee JH, Ahmed O. Endoscopic Management of Pancreatic Cancer. *Surg Oncol Clin N Am.* 2019;28(1):147-59.

101. Lee JH, Kim KM, Cheong JH, Noh SH. Current management and future strategies of gastric cancer. *Yonsei Med J.* 2012;53(2):248-57.

102. Lester P, Gaynor JS. Management of cancer pain. *Vet Clin North Am Small Anim Pract.* 2000;30(4):951-66, ix.

103. Levy MH, Samuel TA. Management of cancer pain. *Semin Oncol.* 2005;32(2):179-93.

104. Li C, Teixeira AF, Zhu HJ, Ten Dijke P. Cancer associated-fibroblast-derived exosomes in cancer progression. *Mol Cancer.* 2021;20(1):154.

105. Lin H, Balic M, Zheng S, Datar R, Cote RJ. Disseminated and circulating tumor cells: Role in effective cancer management. *Crit Rev Oncol Hematol*. 2011;77(1):1-11.
106. Lincoln SB, Soto-Perez-de-Celis E, Chavarri-Guerra Y, Covarrubias-Gomez A, Navarro M, Goss PE. Cancer pain management in Mexico. *BMJ Support Palliat Care*. 2022;12(e2):e271-e6.
107. Litton JK, Burstein HJ, Turner NC. Molecular Testing in Breast Cancer. *Am Soc Clin Oncol Educ Book*. 2019;39:e1-e7.
108. Lopez-Yrigoyen M, Cassetta L, Pollard JW. Macrophage targeting in cancer. *Ann N Y Acad Sci*. 2021;1499(1):18-41.
109. Lorch A. Management of Refractory Germ Cell Cancer. *Am Soc Clin Oncol Educ Book*. 2018;38:324-9.
110. Lovell MR, Luckett T, Boyle FM, Phillips J, Agar M, Davidson PM. Patient education, coaching, and self-management for cancer pain. *J Clin Oncol*. 2014;32(16):1712-20.
111. Lynch HT, Fusaro RM, Lynch JF. Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control. *Future Oncol*. 2007;3(2):169-81.
112. Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. *Int J Mol Sci*. 2020;21(11)
113. Magee D, Bachtold S, Brown M, Farquhar-

- Smith P. Cancer pain: where are we now? *Pain Manag*. 2019;9(1):63-79.
114. Magee DJ, Schutzer-Weissmann J, Pereira EAC, Brown MRD. Neuromodulation techniques for cancer pain management. *Curr Opin Support Palliat Care*. 2021;15(2):77-83.
115. Maltser S, Cristian A, Silver JK, Morris GS, Stout NL. A Focused Review of Safety Considerations in Cancer Rehabilitation. *Pm r*. 2017;9(9s2):S415-s28.
116. Martin RC, 2nd. Management of Locally Advanced Pancreatic Cancer. *Surg Clin North Am*. 2016;96(6):1371-89.
117. Matulonis UA. Management of newly diagnosed or recurrent ovarian cancer. *Clin Adv Hematol Oncol*. 2018;16(6):426-37.
118. McBrien B. Assessment and management of metastatic bone cancer in emergency departments. *Emerg Nurse*. 2021;29(2):20-5.
119. McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical Diagnosis and Management of Breast Cancer. *J Nucl Med*. 2016;57 Suppl 1:9s-16s.
120. ME IJ, Sanz-Pamplona R, Hermitte F, de Miranda N. Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy. *Mol Aspects Med*. 2019;69:123-9.
121. Mendhiratta N, Taneja SS, Rosenkrantz AB. The role of MRI in prostate cancer diagnosis and management. *Future Oncol*. 2016;12(21):2431-43.

122. Missiroli S, Perrone M, Genovese I, Pinton P, Giorgi C. Cancer metabolism and mitochondria: Finding novel mechanisms to fight tumours. *EBioMedicine*. 2020;59:102943.
123. Mohammadzadeh N, Safdari R, Rahimi A. Cancer care management through a mobile phone health approach: key considerations. *Asian Pac J Cancer Prev*. 2013;14(9):4961-4.
124. Mollica V, Di Nunno V, Santoni M, Cimadamore A, Scarpelli M, Lopez-Beltran A, et al. An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. *Expert Rev Mol Diagn*. 2020;20(2):207-17.
125. Mukai M, Komori K, Oka T. Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis. *J Atheroscler Thromb*. 2018;25(10):994-1002.
126. Musa M, Ali A. Cancer-associated fibroblasts of colorectal cancer and their markers: updates, challenges and translational outlook. *Future Oncol*. 2020;16(29):2329-44.
127. Ndiaye M, Kumar R, Ahmad N. Resveratrol in cancer management: where are we and where we go from here? *Ann N Y Acad Sci*. 2011;1215:144-9.
128. Ngeow J, Eng C. PTEN in Hereditary and Sporadic Cancer. *Cold Spring Harb Perspect Med*. 2020;10.(4)
129. Nishikawa H, Goto M, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Cancer Cachexia: Its

- Mechanism and Clinical Significance. *Int J Mol Sci*. 2021;22.(16)
130. Nurudeen S, Hunt KK. Contemporary management of the axilla in breast cancer. *Clin Adv Hematol Oncol*. 2018;16(12):823-31.
131. Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. *J Leukoc Biol*. 2019;106(2):309-22.
132. Omarini C, Thanopoulou E, Johnston SR. Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. *Breast Cancer Res Treat*. 2014;146(2):245-58.
133. Orbach D, Sarnacki S, Brisse HJ, Gauthier-Villars M, Jarreau PH, Tsatsaris V, et al. Neonatal cancer. *Lancet Oncol*. 2013;14(13):e609-20.
134. Paice JA. Cancer pain management and the opioid crisis in America: How to preserve hard-earned gains in improving the quality of cancer pain management. *Cancer*. 2018;124(12):2491-7.
135. Paice JA, Bohlke K, Barton D, Craig DS, El-Jawahri A, Hershman DL, et al. Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline. *J Clin Oncol*. 2023;41(4):914-30.
136. Paice JA, Ferrell B. The management of cancer pain. *CA Cancer J Clin*. 2011;61(3):157-82.
137. Palermo G, Foschi N, D'Agostino D, Sacco E, Bassi P, Pinto F. Local relapse of prostate cancer after primary definitive treatment: the management. *Minerva Urol Nefrol*. 2016;68(3):282-92.



138. Parikh PY, Lillemoe KD. Surgical management of pancreatic cancer--distal pancreatectomy. *Semin Oncol.* 2015;42(1):110-22.
139. Patel TH, Cecchini M. Targeted Therapies in Advanced Gastric Cancer. *Curr Treat Options Oncol.* 2020;21(9):70.
140. Perri G, Prakash L, Katz MHG. Defining and Treating Borderline Resectable Pancreatic Cancer. *Curr Treat Options Oncol.* 2020;21(9):71.
141. Phillips C, Jeffree R, Khasraw M. Management of breast cancer brain metastases: A practical review. *Breast.* 2017;31:90-8.
142. Portenoy RK. Cancer pain. *Epidemiology and syndromes. Cancer.* 1989;63(11 Suppl):2298-307.
143. Portenoy RK, Ahmed E. Cancer Pain Syndromes. *Hematol Oncol Clin North Am.* 2018;32(3):371-86.
144. Prommer EE. Pharmacological Management of Cancer-Related Pain. *Cancer Control.* 2015;22(4):412-25.
145. Prommer EE. Palliative Pharmacotherapy: State-of-the-Art Management of Symptoms in Patients With Cancer. *Cancer Control.* 2015;22(4):403-11.
146. Rabow MW, Petzel MQB, Adkins SH. Symptom Management and Palliative Care in Pancreatic Cancer. *Cancer J.* 2017;23(6):362-73.
147. Rallis KS, Lai Yau TH, Sideris M. Chemoradiotherapy in Cancer Treatment: Rationale and Clinical Applications. *Anticancer*

- Res.* 2021;41(1):1-7.
148. Ramamoorthi G, Kodumudi K, Gallen C, Zachariah NN, Basu A, Albert G, et al. Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities. *Semin Cancer Biol.* 2022;78:78-89.
149. Rami-Porta R, Call S, Doooms C, Obiols C, Sánchez M, Travis WD, et al. Lung cancer staging: a concise update. *Eur Respir J.* 2018;51.(5)
150. Ravi P, Pagliaro LC. Multimodal Therapy in the Management of Advanced Penile Cancer. *Urol Clin North Am.* 2016;43(4):469-79.
151. Rivera-Salgado D, Valverde-Muñoz K, Ávila-Agüero ML. [Febrile neutropenia in cancer patients: management in the emergency room]. *Rev Chilena Infectol.* 2018;35(1):62-71.
152. Romualdi E, Ageno W. Management of recurrent venous thromboembolism in cancer patients. *Thromb Res.* 2016;140 Suppl 1:S128-31.
153. Ryun Park S. Management of gastric cancer: East vs West. *Curr Probl Cancer.* 2015;39(6):315-41.
154. Sabbagh C, Cosse C, Chauffert B, Nguyen-Khac E, Joly JP, Yzet T, et al. Management of colon cancer in patients with cirrhosis: A review. *Surg Oncol.* 2015;24(3):187-93.
155. Salvatorelli E, Menna P, Cantalupo E, Chello M, Covino E, Wolf FI, et al. The concomitant management of cancer therapy and cardiac therapy. *Biochim Biophys Acta.* 2015;1848(10 Pt

B):2727-37.

156. Samuel N, Villani A, Fernandez CV, Malkin D. Management of familial cancer: sequencing, surveillance and society. *Nat Rev Clin Oncol.* 2014;11(12):723-31.

157. Sanchez Varela V, Zhou ES, Bober SL. Management of sexual problems in cancer patients and survivors. *Curr Probl Cancer.* 2013;37(6):319-52.

158. Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. *Lancet.* 2021;398(10305):1075-90.

159. Scarpato KR, Tyson MD, Clark PE. Natural biology and management of nonmuscle invasive bladder cancer. *Curr Opin Oncol.* 2016;28(3):210-5.

160. Selby P, Popescu R, Lawler M, Butcher H, Costa A. The Value and Future Developments of Multidisciplinary Team Cancer Care. *Am Soc Clin Oncol Educ Book.* 2019;39:332-40.

161. Shore ND, Karsh L, Gomella LG, Keane TE, Concepcion RS, Crawford ED. Avoiding obsolescence in advanced prostate cancer management: a guide for urologists. *BJU Int.* 2015;115(2):188-97.

162. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. *Nat Rev Clin Oncol.* 2017;14(9):531-48.

163. Spratt DE, Shore N, Sartor O, Rathkopf D, Olivier K. Treating the patient and not just the cancer: therapeutic burden in prostate cancer.

Prostate Cancer *Prostatic Dis.* 2021;24(3):647-61.

164. Stish BJ, Davis BJ, Mynderse LA, Deufel CL, Choo R. Brachytherapy in the Management of Prostate Cancer. *Surg Oncol Clin N Am.* 2017;26(3):491-513.

165. Strebkova R. Cancer-related Fatigue in Patients with Oncological Diseases: Causes, Prevalence, Guidelines for Assessment and Management. *Folia Med (Plovdiv).* 2020;62(4):679-89.

166. Sun W, Al-Rajabi R, Perez RO, Abbasi S, Ash R, Habr-Gama A. Controversies in Rectal Cancer Treatment and Management. *Am Soc Clin Oncol Educ Book.* 2020;40:1-11.

167. Symer MM, Yeo HL. Recent advances in the management of anal cancer. *F1000Res.* 2018;7.

168. Syrjala KL, Jensen MP, Mendoza ME, Yi JC, Fisher HM, Keefe FJ. Psychological and behavioral approaches to cancer pain management. *J Clin Oncol.* 2014;32(16):1703-11.

169. Tao W, Lagergren J. Clinical management of obese patients with cancer. *Nat Rev Clin Oncol.* 2013;10(9):519-33.

170. Tatarian T, Winter JM. Genetics of Pancreatic Cancer and Its Implications on Therapy. *Surg Clin North Am.* 2016;96(6):1207-21.

171. Tay KJ, Moul JW, Armstrong AJ. Management of Prostate Cancer in the Elderly. *Clin Geriatr Med.* 2016;32(1):113-32.

172. Taylor DK. Influence of Pain and Analgesia on Cancer Research Studies. *Comp Med.*

- 2019;69(6):501-9.
173. Teo MY, Rathkopf DE, Kantoff P. Treatment of Advanced Prostate Cancer. *Annu Rev Med.* 2019;70:479-99.
174. Terzolo M, Daffara F, Ardito A, Zaggia B, Basile V, Ferrari L, et al. Management of adrenal cancer: a 2013 update. *J Endocrinol Invest.* 2014;37(3):207-17.
175. Thielking PD. Cancer pain and anxiety. *Curr Pain Headache Rep.* 2003;7(4):249-61.
176. Tomuleasa C, Zaharie F, Muresan MS, Pop L, Fekete Z, Dima D, et al. How to Diagnose and Treat a Cancer of Unknown Primary Site. *J Gastrointest Liver Dis.* 2017;26(1):69-79.
177. Tong CKW, Lau B, Davis MK. Exercise Training for Cancer Survivors. *Curr Treat Options Oncol.* 2020;21(7):53.
178. Traboulsi SL, Witjes JA, Kassouf W. Contemporary Management of Primary Distal Urethral Cancer. *Urol Clin North Am.* 2016;43(4):493-503.
179. Traves KP, Cokenakes SEH. Breast Cancer Treatment. *Am Fam Physician.* 2021;104(2):171-8.
180. Vallakati A, Konda B, Lenihan DJ, Baliga RR. Management of Cancer Therapeutics-Related Cardiac Dysfunction. *Heart Fail Clin.* 2018;14(4):553-67.
181. Vendramin R, Litchfield K, Swanton C. Cancer evolution: Darwin and beyond. *Embo j.* 2021;40(18):e108389.

182. Vishwakarma M, Piddini E. Outcompeting cancer. *Nat Rev Cancer.* 2020;20(3):187-98.
183. Voznesensky M, Annam K, Kreder KJ. Understanding and Managing Erectile Dysfunction in Patients Treated for Cancer. *J Oncol Pract.* 2016;12(4):297-304.
184. Wadasadawala T, Vadgaonkar R, Bajpai J. Management of Isolated Locoregional Recurrences in Breast Cancer: A Review of Local and Systemic Modalities. *Clin Breast Cancer.* 2017;17(7):493-502.
185. Wang LY, Ganly I. Nodal metastases in thyroid cancer: prognostic implications and management. *Future Oncol.* 2016;12(7):981-94.
186. Wang Y, Du J, Wu X, Abdelrehem A, Ren Y, Liu C, et al. Crosstalk between autophagy and microbiota in cancer progression. *Mol Cancer.* 2021;20(1):163.
187. Werner S, Heidrich I, Pantel K. Clinical management and biology of tumor dormancy in breast cancer. *Semin Cancer Biol.* 2022;78:49-62.
188. Willis D, Kamat AM. Nonurothelial bladder cancer and rare variant histologies. *Hematol Oncol Clin North Am.* 2015;29(2):237-52, viii.
189. Yates P. Symptom Management and Palliative Care for Patients with Cancer. *Nurs Clin North Am.* 2017;52(1):179-91.
190. Yoo BC, Kim KH, Woo SM, Myung JK. Clinical multi-omics strategies for the effective cancer management. *J Proteomics.* 2018;188:97-106.

191. Zahalka AH, Frenette PS. Nerves in cancer. *Nat Rev Cancer*. 2020;20(3):143-57.
192. Zhang W, Wang Q, Yang Y, Zhou S, Zhang P, Feng T. The role of exosomal lncRNAs in cancer biology and clinical management. *Exp Mol Med*. 2021;53(11):1669-73.
193. Zhou L, Jilderda LJ, Foijer F. Exploiting aneuploidy-imposed stresses and coping mechanisms to battle cancer. *Open Biol*. 2020;10(9):200148.
194. Zhou N, Rajaram R, Hofstetter WL. Management of Locally Advanced Esophageal Cancer. *Surg Oncol Clin N Am*. 2020;29(4):631-46.
195. Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. *J Clin Oncol*. 2005;23(32):8247-52.
196. Blackwood L. Cats with cancer: where to start. *J Feline Med Surg*. 2013;15(5):366-77.
197. Brink-Huis A, van Achterberg T, Schoonhoven L. Pain management: a review of organisation models with integrated processes for the management of pain in adult cancer patients. *J Clin Nurs*. 2008;17(15):1986-2000.
198. Burgers K, Moore C, Bednash L. Care of the Colorectal Cancer Survivor. *Am Fam Physician*. 2018;97(5):331-6.
199. Byock I. Completing the continuum of cancer care: integrating life-prolongation and palliation. *CA Cancer J Clin*. 2000;50(2):123-32.
200. Candido KD, Kusper TM, Knezevic NN.

- New Cancer Pain Treatment Options. *Curr Pain Headache Rep*. 2017;21(2):12.
201. Cersosimo RJ. Management of advanced colorectal cancer, Part 2. *Am J Health Syst Pharm*. 2013;70(6):491-506.
  202. Chen CL, Steingart R. Cardiac disease and heart failure in cancer patients: is our training adequate to provide optimal care? *Heart Fail Clin*. 2011;7(3):357-62.
  203. Cheng FK. Cancer-Induced Bone Pain Management Through Buddhist Beliefs. *J Relig Health*. 2017;56(6):2251-66.
  204. Cherkassky L, D'Angelica M. Gallbladder Cancer: Managing the Incidental Diagnosis. *Surg Oncol Clin N Am*. 2019;28(4):619-30.
  205. Ciccamese C, Modena A, Tortora G, Massari F. Kidney cancer and 2014: is innovation really over? *Future Oncol*. 2015;11(9):1437-49.
  206. Connor AA, Gallinger S. Hereditary Pancreatic Cancer Syndromes. *Surg Oncol Clin N Am*. 2015;24(4):733-64.
  207. Cristofanilli M, Buzdar AU, Hortobágyi GN. Update on the management of inflammatory breast cancer. *Oncologist*. 2003;8(2):141-8.
  208. de Leon-Casasola OA. Current developments in opioid therapy for management of cancer pain. *Clin J Pain*. 2008;24 Suppl 10:S3-7.
  209. Dotan E, Browner I, Hurria A, Denlinger C. Challenges in the management of older patients with colon cancer. *J Natl Compr Canc Netw*. 2012;10(2):213-24; quiz 25.

210. French J, Sutcliffe SB. Planning for cancer control programs: Leadership considerations. *Healthc Manage Forum*. 2018;31(1):5-8.
211. Guerard EJ, Cleary JF. Managing Cancer Pain in Older Adults. *Cancer J*. 2017;23(4):242-5.
212. Gwynn ES, Clark PE. Bladder cancer. *Curr Opin Oncol*. 2006;18(3):277-83.
213. Herman JM, Hoffman JP, Thayer SP, Wolff RA. Management of the Primary Tumor and Limited Metastases in Patients With Metastatic Pancreatic Cancer. *J Natl Compr Canc Netw*. 2015;13(5):e29-36.
214. Islam J, Harris GD. Cancer Survivor Health Needs for Women. *Prim Care*. 2018;45(4):659-76.
215. Kamil Zaidan H, Jasim Al-Khafaji HH, Al-Dolaimy F, Abed Hussein S, Otbah Farqad R, Thabit D, et al. Exploring the Therapeutic Potential of Lawsone and Nanoparticles in Cancer and Infectious Disease Management. *Chem Biodivers*. 2024;21(4):e202301777.
216. Klotz L. Active surveillance for prostate cancer: overview and update. *Curr Treat Options Oncol*. 2013;14(1):97-108.
217. Kovács D, Igaz N, Gopisetty MK, Kiricsi M. Cancer Therapy by Silver Nanoparticles: Fiction or Reality? *Int J Mol Sci*. 2022;23.(2)
218. Kuppala MB, Syed SB, Bandaru S, Varre S, Akka J, Mundulru HP. Immunotherapeutic approach for better management of cancer--role of IL-18. *Asian Pac J Cancer Prev*. 2012;13(11):5353-61.

219. Lakha SF, Pennefather P, Badr HE, Mailis-Gagnon A. Health Services for Management of Chronic Non-Cancer Pain in Kuwait: A Case Study Review. *Med Princ Pract*. 2016;25 Suppl 1(Suppl 1):29-42.
220. Lau WF, Ware R, Herth FJ. Diagnostic evaluation for interventional bronchoscopists and radiologists in lung cancer practice. *Respirology*. 2015;20(5):705-14.
221. Leung D, Krishnamoorthy S, Schwartz L, Divgi C. Imaging approaches with advanced prostate cancer: techniques and timing. *Can J Urol*. 2014;21(2 Supp 1):42-7.
222. Levy MR, Fann JR. Assessment and management of psychiatric issues during cancer treatment. *Curr Pain Headache Rep*. 2008;12(4):262-9.
223. Lourenco AP, Mainiero MB. Incorporating Imaging Into the Locoregional Management of Breast Cancer. *Semin Radiat Oncol*. 2016;26(1):17-24.
224. Massingham LJ, De Souza A. Current Indications for Consideration of Evaluation for Hereditary Cancer Predisposition Syndromes and How They Can Change Management. *R I Med J* (2013). 2020;103(3):20-4.
225. McKenna S, Eatock M. The medical management of pancreatic cancer: a review. *Oncologist*. 2003;8(2):149-60.
226. Momesso DP, Vaisman F, Cordeiro de Noronha Pessoa CH, Corbo R, Vaisman M. Small

differentiated thyroid cancer: time to reconsider clinical management and treatment. *Surg Oncol.* 2012;21(4):257-62.

227. Padma S, Sundaram PS. Radioiodine as an adjuvant therapy and its role in follow-up of differentiated thyroid cancer. *J Cancer Res Ther.* 2016;12(3):1109-13.

228. Pagano L, Dragonetti G, De Carolis E, Veltri G, Del Principe MI, Busca A. Developments in identifying and managing mucormycosis in hematologic cancer patients. *Expert Rev Hematol.* 2020;13(8):895-905.

229. Ramirez AT, Gibelli B, Tradati N, Giugliano G, Zurlo V, Grosso E, et al. Surgical management of thyroid cancer. *Expert Rev Anticancer Ther.* 2007;7(9):1203-14.

230. Salehi S, Stålberg K, Marcickiewicz J, Rosenberg P, Falconer H. [Increasingly better diagnosis and treatment of endometrial cancer]. *Lakartidningen.* 2015;112.

231. Saltz LB. Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why. *Cancer J.* 2016;22(3):232-5.

232. Saxena R, Rida PC, Kucuk O, Aneja R. Ginger augmented chemotherapy: A novel multitarget nontoxic approach for cancer management. *Mol Nutr Food Res.* 2016;60(6):1364-73.

233. Schmidt BL. The neurobiology of cancer pain. *Neuroscientist.* 2014;20(5):546-62.

234. Shoemaker LK, Estfan B, Induru R, Walsh TD. Symptom management: an important part of

cancer care. *Cleve Clin J Med.* 2011;78(1):25-34.

235. Singh CK, George J, Ahmad N. Resveratrol-based combinatorial strategies for cancer management. *Ann N Y Acad Sci.* 2013;1290(1):113-21.

236. Slev VN, Mistiaen P, Pasman HR, Verdonck-de Leeuw IM, van Uden-Kraan CF, Francke AL. Effects of eHealth for patients and informal caregivers confronted with cancer: A meta-review. *Int J Med Inform.* 2016;87:54-67.

237. Tray N, Taff J, Adams S. Therapeutic landscape of metaplastic breast cancer. *Cancer Treat Rev.* 2019;79:101888.

238. Vervandier-Fasseur D, Latruffe N. The Potential Use of Resveratrol for Cancer Prevention. *Molecules.* 2019;24.(24)

239. Watson M, Dunn J. The multidisciplinary art and science of cancer care: integrating psycho-oncology. *Future Oncol.* 2016;12(24):2775-8.

240. Weiser MR, Beets-Tan R, Beets G. Management of complete response after chemoradiation in rectal cancer. *Surg Oncol Clin N Am.* 2014;23(1):113-25.

241. Wong ALA, Bellot GL, Hirpara JL, Pervaiz S. Understanding the cancer stem cell phenotype: A step forward in the therapeutic management of cancer. *Biochem Pharmacol.* 2019;162:79-88.

242. Wortzel J, Spiegel D. Hypnosis in Cancer Care. *Am J Clin Hypn.* 2017;60(1):4-17.

243. Yete S, Saranath D. MicroRNAs in oral cancer: Biomarkers with clinical potential. *Oral*

- Oncol. 2020;110:105002.
244. Zinman LN, Vanni AJ. Management of Proximal Primary Urethral Cancer: Should Multidisciplinary Therapy Be the Gold Standard? *Urol Clin North Am.* 2016;43(4):505-13.
245. Abadi SAH, Atbaei R, Forouhi M, Falaverjani HG, Moazamiyanfar R, Rezaei M, et al. Preventive and Therapeutic Approaches in Medical Departments During the COVID-19 Pandemic. *Kindle.* 2022;2(1):1-216.
246. Ahadiat S-A, Atighi J, Forouhi M, Mashatan N, Ghahremaniyeh Z, Radmanesh M, et al. Diagnosis and Management of Complications of COVID-19. *Kindle.* 2022;2(1):1-113.
247. Ahadiat S-A, Barati R, Moghadam NS, Samami E, Ghiabi S, Alyari M, et al. Role of Oxidative Stress and Antioxidants in Malignancies. *Kindle.* 2022;2(1):1-122.
248. Ahadiat S-A, Falaverjani HG, Shabani M, Abadi SAH, Moazamiyanfar R, Rajabi SK, et al. The Role of Stem Cells in Treatment of Autoimmune Diseases. *Kindle.* 2022;2(1):1-136.
249. Ahadiat S-A, Ghazalgoo A, Abadi SAH, Falaverjani HG, Bagherianlemraski M, Namazifar F, et al. Role of Vitamin D in Pathogenesis, Diagnosis, and Treatment of Inflammatory Diseases. *Kindle.* 2022;2(1):1-119.
250. Ahadiat S-A, Kamrani K, Fard AM, Bagherianlemraski M, Rahimpour E, Jamali M, et al. Role of Blood Groups in Risk, Severity, Prognosis, and Response to Treatment of the

- Diseases. *Kindle.* 2022;2(1):1-130.
251. Ahadiat S-A, Shirazinia M, Shirazinia S, Garousi S, Mottahedi M, Jalali AB, et al. Role of Telemedicine in Management of Patients During the COVID-19 Pandemic. *Kindle.* 2022;2(1):1-191.
252. Amini N, Azimzadeh M, Dosar MD, Fard AM, Habibzadeh N, Yahyazadehjasour S, et al. Role of Microbiome, Infection, and Inflammation in Autoimmune Diseases. *Kindle.* 2023;3(1):1-102.
253. Fard AM, Nikbakht T, Babaei N, Pouyamanesh M, Afzalian A, Kharazmkia A, et al. Role of medicinal plants in treatment of inflammatory diseases. *Kindle.* 2022;2(1):1-139.
254. Farrokhi M, Khouzani SJ, Farrokhi M, Jalayeri H, Faranoush P, Babaei M, et al. Artificial Intelligence and Deep Learning for Screening and Risk Assessment of Cancers. *Kindle.* 2024;4(1):1-140.
255. Farrokhi M, Moeini A, Taheri F, Farrokhi M, Khodashenas M, Babaei M, et al. AI-assisted Screening and Prevention Programs for Diseases. *Kindle.* 2023;3(1):1-209.
256. Farrokhi M, Moeini A, Taheri F, Farrokhi M, Mostafavi M, Ardakan AK, et al. Artificial Intelligence in Cancer Care: From Diagnosis to Prevention and Beyond. *Kindle.* 2023;3(1):1-149.
257. Farrokhi M, Rigi A, Mangouri A, Fadaei M, Shabani E, Mashouf P, et al. Role of Antioxidants in Autoimmune Diseases. *Kindle.* 2021;1(1):1-107.
258. Farrokhi M, Shabani S, Rigi A, Seighalani HH, Pazhooha M, Bagheri S, et al. Academic

- Textbook: Anatomy, Pathophysiology, and Treatment of Pain. Kindle. 2021;1(1):1-123.
259. Farrokhi M, Taheri F, Bayat Z, Damiri M, Farrokhi M, Ghadirzadeh E, et al. Role of Lifestyle Medicine in the Prevention and Treatment of Diseases. Kindle. 2024;4(1):1-219.
260. Farrokhi M, Taheri F, Farrokhi M, Emtiazi N, Talebi M, Akbari A, et al. Human and AI: Collaborative Medicine in the Age of Technology. Kindle. 2024;4(1):1-160.
261. Farrokhi M, Taheri F, Farrokhi M, Moeini A, Toyserkani SH, Shahali A, et al. Anti-Aging Strategies to Prevent Diseases: Promoting Longevity and Optimal Health. Kindle. 2024;4(1):1-194.
262. Farrokhi M, Taheri F, Karami E, Khorram R, Sarnaghy FJ, Mirbolook A, et al. Effects of Environmental Factors and Epigenetic on Health and the Development of Diseases. Kindle. 2023;3(1):1-186.
263. Farrokhi M, Taheri F, Khouzani PJ, Rahmani E, Tavakoli R, Fard AM, et al. Role of precision medicine and personalized medicine in the treatment of diseases. Kindle. 2023;3(1):1-164.
264. Farrokhi M, Taheri F, Moeini A, Farrokhi M, Alireza MZS, Farahmandsadr M, et al. Artificial Intelligence for Remote Patient Monitoring: Advancements, Applications, and Challenges. Kindle. 2024;4(1):1-261.
265. Farrokhi M, Taheri F, Moeini A, Farrokhi M, Khouzani PJ, Ghadirzadeh E, et al. Artificial

- Intelligence for Drug Development, Personalized Prescriptions, and Adverse Event Prediction. Kindle. 2024;4(1):1-180.
266. Farrokhi M, Taheri F, Moeini A, Farrokhi M, Rabiei S, Farahmandsadr M, et al. Sex and Gender Differences in the Pathogenesis and Treatment of Diseases. Kindle. 2023;3(1):1-168.
267. Farrokhi M, Vafaei S, Bidares M, Siami H, Rigi A, Hannaniyan M, et al. Diagnosis and Treatment of Manifestations of COVID-19. Kindle. 2021;1(1):1-170.
268. Ghalamkarpour N, Fard AM, Babazadeh A, Nikseresht H, Feyzmanesh A, Soltani R, et al. Role of Biomarkers in Risk, Diagnosis, Response to Treatment, and Prognosis of the Autoimmune Diseases. Kindle. 2022;2(1):1-124.
269. Poudineh M, Poudineh S, Hosseini Z, Pouramini S, Fard SS, Fadavian H, et al. Risk Factors for the Development of Cancers. Kindle. 2023;3(1):1-118.
270. Poudineh S, Poudineh M, Roohinezhad R, Khorram R, Fard AM, Barzegar F, et al. Role of Vitamins in Pathogenesis and Treatment of Cancers. Kindle. 2023;3(1):1-110.
271. Rahmani E, Fard AM, Baghsheikhi H, Hosseini Z, Mashaollahi A, Atighi J, et al. Role of Selenium in Pathogenesis and Treatment of the Autoimmune Diseases. Kindle. 2022;2(1):1-131.
272. Rahmani E, Rezaei M, Tavakoli R, Ghadirzadeh E, Sarnaghy FJ, Khorram R, et al. Role of Regenerative Medicine in the Treatment of



Diseases. Kindle. 2023;3(1):1-184.

273. Rezaei M, Rahmani E, Khouzani SJ, Rahmanna M, Ghadirzadeh E, Bashghareh P, et al. Role of artificial intelligence in the diagnosis and treatment of diseases. Kindle. 2023;3(1):1-160.

274. Rezaei M, Saei S, Khouzani SJ, Rostami ME, Rahmanna M, Manzelat AMR, et al. Emerging Technologies in Medicine: Artificial Intelligence, Robotics, and Medical Automation. Kindle. 2023;3(1):1-184.

275. Rezaei T, Khouzani PJ, Khouzani SJ, Fard AM, Rashidi S, Ghazalgoo A, et al. Integrating Artificial Intelligence into Telemedicine: Revolutionizing Healthcare Delivery. Kindle. 2023;3(1):1-161.

276. Tabatabaei SOH, Moazamiyanfar R, Fard AM, Salemi MH, Masjedi MNK, Yazdani Y, et al. Academic Textbook: The Role of Melatonin in Pathogenesis and Treatment of Autoimmune Diseases. Kindle. 2022;2(1):1-126.

277. Taheri F, Farrokhi M, Fard AM, Rahmani E, Soltani R, Shamsedanesh S, et al. Role of Micronutrients and Nutrition in Prevention and Treatment of Cancers. Kindle. 2023;3(1):1-102.

278. Taheri F, Rahmani E, Fard SS, Rezaei M, Ayati A, Farhoudian A, et al. Aging Process and Related Diseases. Kindle. 2023;3(1):1-117.

279. Talaie R, Fard SS, Forouhi M, Fard AM, Fard TM, Dadashzadehasl N, et al. Applications, Limitations, and Guidelines for the Use of Telemedicine in Medical Departments. Kindle.

2022;2(1):1-118.

280. Yarmohammadi B, Rigi A, Sahebkar F, Ahadiat S-A, Gharei F, Heydarian P, et al. Guidelines for Providing Services in Medical Departments During the COVID-19 Pandemic. Kindle. 2022;2(1):1-193.

281. Mokhtari M, Tavakkoli H, Rafiee A, Dibaj R. Assessment of relationship between active ulcerative colitis and cytomegalovirus infection among Iranian patients. Adv Biomed Res. 2012;1:19.

Proof